Home | Site Map | Contact Us | Bookmark
 
  Single Disease Educational Content
  Multi-Disease
Educational Content
  Other Resources
  About CLDF
 
 

Hepatitis C Virus (HCV)
  Additional content on this specific disease state can be found in the:     Click on another disease specific
area listed above to view content
 

Liver News Library
 
 
 
 
Educational Objectives
After completing this activity, the participants should be better able to:
• Recognize the benefits of using boceprevir or telaprevir in combination with pegylated interferon and ribavirin in the treatment of genotype 1 hepatitis C
• Describe response guided therapy with approved protease inhibitors in combination with pegylated interferon and ribavirin
• Review primary adverse reactions seen in registration trials of protease inhibitors; identify appropriate strategies for management of adverse reactions
 
Statement of Need/Program Overview
The goal of this program is to improve healthcare providers competency in understanding the long-term effects and potential liver related complications of chronic liver diseases. The program will also provide education on management options and outcomes of treatment.
 
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, physician assistants, nurse practitioners, internal medicine and primary care physicians involved in the care of patients with chronic liver disease.
 

 View details
 
 
Jointly sponsored by Purdue University School of Pharmacy and the Chronic Liver Disease Foundation. This activity supported by: Kadmon Pharmaceuticals, OraSure Technologies and Vertex Pharmaceuticals.
 
  
       

  

Hepatology 2009 Current Perspectives on Chronic Liver Disease   Educational Webcast
       

  

Treatment of Genotype 1 Nonresponders   Educational Webcast
  Presented by: Fred Poordad, MD    

  

Treatment of Hepatitis C Genotype 1 Infected Patients   Educational Webcast
  Presented by: Sammy Saab, MD    

  

Optimizing Outcomes: Emerging Therapies for HCV   Symposium Webcast
  2006    
 
 
 
Hepatology 2010 Slides  
Current Perspectives on Chronic Liver Disease  
     
 
 

HCV Slide Archive

  
     
 
 
HCV 2009
HCV Genotypes 2 & 3
Approach to Patients that Failed to Achieve Sustained Viral Response
HCV Genotype 1
Hepatology 2009 Slides: Current Perspectives on Chronic Liver Disease
 
HCV 3rd Edition Slides
Epidemiology and Natural History
Diagnosis and Monitoring
Treatment Special Populations
  Overview   African Americans
  Genotype 1   Hispanic Americans
  Genotype 2/3   HCV/HIV Co-infected
  Retreatment   HCV and Alcohol
  Side Effects   Liver Transplant
  Emerging Therapies   Acute Infection
 
HCV 2nd Edition Slides
Epidemiology and Natural History Diagnosis and Monitoring
Treatment Side Effects and Management Treatment
Special Patient Populations  
   
HCV - AASLD 2005    
Emerging Therapies in HCV:'Building the Bridge to Improved Outcomes'
Ribavirin Analogues  
Immunomodulators  
Caspase Inhibitors  
Specific Small Molecule Inhibitors  
   
HCV 1st Edition Slides
Epidemiology and Natural History  
Molecular Tools for the Diagnosis and Monitoring of Hepatitis C
Treatment of HCV  
Prevention of Coinfection/Superinfection  
Early Assessment of Response  
Histologic Response to Treatment  
Adherence and SE Management  
 
     
 
 
  1. Gambarin-Gelwan M, Jacobson IM. Curr Gastroenterol Rep. 2011 Dec 10. [Epub ahead of print]
    Source Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, 1305 York Ave, 4th floor, New York, NY, 10021, USA, mag2046@med.cornell.edu.

  2. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients
    Butt AA, Kanwal F. Clin Infect Dis. 2012 Jan;54(1):96-104. Epub 2011 Dec 7.

  3. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Clin Infect Dis. 2011 Dec 14. [Epub ahead of print]

  4. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation
    Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S, Zelber-Sagi S, Rozovski U, Leshno M, Oren R. World J Gastroenterol. 2011 Dec 7;17(45):5007-13.

  5. Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
    Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, Imazeki F, Yokosuka O. PLoS One. 2011;6(12):e28617. Epub 2011 Dec 12.

  6. Neutralizing antibody response to hepatitis C virus
    Wang Y, Keck ZY, Foung SK. Viruses. 2011 Nov;3(11):2127-45. Epub 2011 Nov 2.

  7. Current Perspective of HCV NS5B Inhibitors: A Review
    Patil VM, Gupta SP, Samanta S, Masand N. Curr Med Chem. 2011 Dec 1;18(36):5564-97.

  8. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
    Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Clin Infect Dis. 2011 Dec 14. [Epub ahead of print]

  9. HCV and HCC: Clinical Update and a Review of HCC-Associated Viral Mutations in the Core Gene
    Ahmad J, Eng FJ, Branch AD. Semin Liver Dis. 2011 Nov;31(4):347-55. Epub 2011 Dec 21.

  10. Transmission of hepatitis C virus through transplanted organs and tissue - kentucky and massachusetts, 2011
    Centers for Disease Control and Prevention (CDC).AbstractMMWR Morb Mortal Wkly Rep. 2011 Dec 23;60:1697-700.

  11. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B
    Dahari H, Guedj J, Perelson AS, Layden TJ. Curr Hepat Rep. 2011 Jul 2;10(3):214-227.

  12. Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference?
    Hope V, Parry JV, Marongui A, Ncube F. J Viral Hepat. 2012 Jan;19(1):55-64. doi: 10.1111/j.1365-2893.2010.01415.x. Epub 2011 Jan 7.

  13. The dependence of viral RNA replication on co-opted host factors
    Nagy PD, Pogany J. Nat Rev Microbiol. 2011 Dec 19. doi: 10.1038/nrmicro2692. [Epub ahead of print]

  14. Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype
    Motomura T, Koga E, Taketomi A, Fukuhara T, Mano Y, Muto J, Konishi H, Toshima T, Uchiyama H, Yoshizumi T, Shirabe K, Maehara Y. Hepatol Res. 2011 Dec 19. doi: 10.1111/j.1872-034X.2011.00927.x. [Epub ahead of print]

  15. A summary of the 18th international symposium on hepatitis C virus and related viruses
    Polyak SJ, Morishima C, Scott JD, Cox A, de Araújo ES, Higgs MR, Loo YM, Golden-Mason L, Lindenbach BD, Baumert TF, Randall G, Gale M Jr. Gastroenterology. 2012 Jan;142(1):e1-5.

  16. Telaprevir: An oral protease inhibitor for hepatitis C virus infection
    Kim JJ, Culley CM, Mohammad RA. Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33.

  17. HCV routes of transmission: what goes around comes around
    Alter MJ. Semin Liver Dis. 2011 Nov;31(4):340-6. Epub 2011 Dec 21.

  18. IL28B polymorphisms influence stage of the liver fibrosis and spontaneousor interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection
    Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, Renda MC, Pitrolo L, Lo Pinto MC, Rizzo M, Fiorenza F, Gerardi C, Grimaudo S, Di Cristina A, Levrero M, Craxi' A. Haematologica. 2011 Dec 16. [Epub ahead of print]

  19. Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy
    Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, Kudo M. Digestion. 2011;84 Suppl 1:56-61. Epub 2011 Dec 2.

  20. Interleukin28B and Inosine Triphosphatase Help to Personalize Hepatitis C Treatment
    Tanaka Y. Digestion. 2011;84 Suppl 1:50-5. Epub 2011 Dec 2.

  21. What is killing people with hepatitis C virus infection?
    Grebely J, Dore GJ. Semin Liver Dis. 2011 Nov;31(4):331-9. Epub 2011 Dec 21.

  22. Hepatitis C virus infection and genetic susceptibility to therapy
    Sibbing B, Nattermann J. J Gastrointestin Liver Dis. 2011 Dec;20(4):397-406.

  23. Determinants of Serum Alpha-Fetoprotein Levels in Hepatitis C Infected Patients
    Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Dec 6. [Epub ahead of print]

  24. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection
    Nehra V, Rizza SA, Talwani R, Temesgen Z. Drugs Today (Barc). 2011 Nov;47(11):829-37.

  25. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients
    Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. PLoS One. 2011;6(12):e26783. Epub 2011 Dec 2.

  26. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C-associated cryoglobulinemic vasculitis
    Sneller MC, Hu Z, Langford CA. Arthritis Rheum. 2011 Dec 6. doi: 10.1002/art.34322. [Epub ahead of print]

  27. Sperm DNA damage in patients with chronic viral C hepatitis
    La Vignera S, Condorelli RA, Vicari E, D'Agata R, Calogero AE. Eur J Intern Med. 2012 Jan;23(1):e19-24. Epub 2011 Sep 3.

  28. Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther.
    Muir AJ. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14.

  29. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C
    Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS; for the HALT-C Trial Group. Liver Int. 2011 Nov 22. doi: 10.1111/j.1478-3231.2011.02686.x. [Epub ahead of print]

  30. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Ann Hepatol. 2012 Jan;11(1):15-31.

  31. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus
    Patel K, Friedrich-Rust M, Lurie Y, Grigorescu M, Stanciu C, Lee CM, Schiff ER, Häussinger D, Manns MP, Gerken G, Colle I, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG, Zeuzem S. World J Gastroenterol. 2011 Nov 7;17(41):4581-9.

  32. Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors) HCV Resistant Mutants among Treatment Naive Infected Individuals
    Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruíz-Pacheco JA, Cazares F, Vaughan G. J Clin Microbiol. 2011 Nov 23. [Epub ahead of print]

  33. Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients
    Jang JY, Jeong SW, Cheon SR, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Kim HS, Jin SY, Kim YS, Kim BS. Korean J Hepatol. 2011 Sep;17(3):206-12. doi: 10.3350/kjhep.2011.17.3.206.

  34. Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era
    Poordad F, Chee GM. Curr Gastroenterol Rep. 2011 Nov 22. [Epub ahead of print]

  35. Female Sex and IL28B, a Synergism for Spontaneous Viral Clearance in Hepatitis C Virus (HCV) Seroconverters from a Community-Based Cohort
    van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, Coutinho RA, van Baarle D, Prins M. PLoS One. 2011;6(11):e27555. Epub 2011 Nov 15.

  36. Association between Chronic Viral Hepatitis Infection and Breast Cancer Risk: a Nationwide Population-based Case-control Study
    Su FH, Chang SN, Chen PC, Sung FC, Su CT, Yeh CC. BMC Cancer. 2011 Nov 24;11(1):495. [Epub ahead of print]

  37. Telaprevir for the treatment of chronic hepatitis C infection
    Muir AJ. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14.

  38. Absenteeism and productivity among employees being treated for hepatitis C
    Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Am J Manag Care. 2011 Oct;17(10):657-64.

  39. The natural history of hepatitis C virus infection acquired during childhood
    Robinson JL, Doucette K. Liver Int. 2011 Sep 11. doi: 10.1111/j.1478-3231.2011.02633.x. [Epub ahead of print]

  40. Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade
    Lai M, Afdhal NH. Am J Gastroenterol. 2011 Dec;106(12):2121-2. doi: 10.1038/ajg.2011.343.

  41. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and ?-fetoprotein levels
    Kajiwara E, Ooho A, Yamashita N. Hepatol Res. 2011 Dec 5. doi: 10.1111/j.1872-034X.2011.00916.x. [Epub ahead of print]

  42. Hepatitis C Virus Infects the Endothelial Cells of the Blood-Brain Barrier
    Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA. Gastroenterology. 2011 Nov 30. [Epub ahead of print]

  43. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent HCV after liver transplantation: Systematic review and meta-analysis
    Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Liver Transpl. 2011 Dec 5. doi: 10.1002/lt.22460. [Epub ahead of print]

  44. A seven gene signature of the recipient predicts progression of fibrosis after liver transplantation for hepatitis C infection
    do O NT, Eurich D, Schmitz P, Schmeding M, Heidenhain C, Bahra M, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE. Liver Transpl. 2011 Dec 5. doi: 10.1002/lt.22475. [Epub ahead of print]

  45. Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C
    Hoefs JC, Aulakh VS, Ilagan BJ. Dig Dis Sci. 2011 Dec 4. [Epub ahead of print]

  46. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus
    Tungol A, Rademacher K, Schafer JA. J Manag Care Pharm. 2011 Nov;17(9):685-94.

  47. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection
    Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A. Mol Med Report. 2011 Nov 1. doi: 10.3892/mmr.2011.655. [Epub ahead of print]

  48. Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3
    Lee SS, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, Hilzenrat N, Balshaw R, Usaty C, Myers RP. Aliment Pharmacol Ther. 2011 Nov 2. doi: 10.1111/j.1365-2036.2011.04911.x. [Epub ahead of print]

  49. Causes and evaluation of mildly elevated liver transaminase levels
    Oh RC, Hustead TR. Am Fam Physician. 2011 Nov 1;84(9):1003-8.

  50. The role of neutralising antibodies in hepatitis C virus infection
    Edwards V, Tarr AW, Urbanowicz R, Ball J. J Gen Virol. 2011 Nov 2. [Epub ahead of print]

  51. Novel Approach for Quantification of Hepatitis C Virus in Liver Cirrhosis Using Real-Time Reverse Transcriptase PCR
    Maudar KK, Gandhi P, Mishra PK, Varshney S, Punde R, Bhargav A. J Gastrointest Surg. 2011 Nov 3. [Epub ahead of print]

  52. Boceprevir
    Rizza SA, Talwani R, Nehra V, Temesgen Z. Drugs Today (Barc). 2011 Oct;47(10):743-51.

  53. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
    Reddy KR, Belle SH, Fried MW, Afdhal NH, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM. Clin Trials. 2011 Nov 4. [Epub ahead of print]

  54. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B
    Li S, Hu P, Zhang QQ, Liu YH, Hu HD, Zhang DZ, Ren H. Hepat Mon. 2011 Mar 1;11(3):163-172.

  55. Recombination in hepatitis C virus
    González-Candelas F, López-Labrador FX, Bracho MA. Viruses. 2011 Oct;3(10):2006-24. Epub 2011 Oct 24.

  56. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy
    Hung CH, Chen CH, Lu SN, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM. Antiviral Res. 2011 Oct 28. [Epub ahead of print]

  57. Implications of rapid virological response in hepatitis C therapy in the US veteran population
    Hwang EW, Thomas IC, Cheung R, Backus LI. Aliment Pharmacol Ther. 2011 Nov 7. doi: 10.1111/j.1365-2036.2011.04903.x. [Epub ahead of print]

  58. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Kwong AD, Kauffman RS, Hurter P, Mueller P. Nat Biotechnol. 2011 Nov 8;29(11):993-1003. doi: 10.1038/nbt.2020.

  59. Hepatitis C core Ag and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow-up?
    Hosseini-Moghaddam S, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazzulli T. Rev Med Virol. 2011 Nov 24. doi: 10.1002/rmv.717. [Epub ahead of print]

  60. Economic model of a birth cohort screening program for hepatitis C virus
    McGarry LJ, Pawar VS, Parekh HH, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Hepatology. 2011 Dec 2. doi: 10.1002/hep.25510. [Epub ahead of print]

  61. Role of LDL receptor in the hepatitis c virus life cycle
    Albecka A, Belouzard S, de Beeck AO, Descamps V, Goueslain L, Bertrand-Michel J, Tercé F, Duverlie G, Rouillé Y, Dubuisson J. Hepatology. 2011 Nov 26. doi: 10.1002/hep.25501. [Epub ahead of print]

  62. Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy
    Lötsch J, Hofmann WP, Schlecker C, Zeuzem S, Geisslinger G, Ultsch A, Doehring A. Pharmacogenomics. 2011 Dec;12(12):1729-40.

  63. Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C
    Falleti E, Cmet S, Fabris C, Bitetto D, Cussigh A, Fornasiere E, Bignulin E, Feruglio C, Mosanghini E, Fontanini E, Pirisi M, Toniutto P. Cytokine. 2011 Nov 26. [Epub ahead of print]

  64. Hepatitis C and non-Hodgkin lymphoma: The clinical perspective
    Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatology. 2011 Nov 26. doi: 10.1002/hep.25499. [Epub ahead of print]

  65. Diabetes Mellitus Following Liver Transplantation in Patients With Hepatitis C Virus: Risks and Consequences
    Gane EJ. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03854.x. [Epub ahead of print]

  66. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C
    Ochi H, Hayes CN, Abe H, Hayashida Y, Uchiyama T, Kamatani N, Nakamura Y, Chayama K. J Infect Dis. 2011 Nov 28. [Epub ahead of print]

  67. Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study
    Harris HE, Costella A, Amirthalingam G, Alexander G, Ramsay ME, Andrews N; the UK HCV National Register Collaborators. Epidemiol Infect. 2011 Nov 29:1-8. [Epub ahead of print]

  68. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy
    Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Eur J Gastroenterol Hepatol. 2011 Nov 18. [Epub ahead of print]

  69. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study
    Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T. J Gastroenterol. 2011 Nov 23. [Epub ahead of print]

  70. 65-gene-based risk score classifier predicts overall survival in hepatocellular carcinoma
    Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24813. [Epub ahead of print]

  71. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?
    Berry K, Ioannou GN. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03853.x. [Epub ahead of print]

  72. Subtle Hepatocellular Carcinoma: A Persisting Role for Alpha-Fetoprotein Monitoring in High-Risk Patients with Cirrhosis
    Schlansky B, Dobos N, Zaman A. Case Rep Gastroenterol. 2011 Sep;5(3):565-568. Epub 2011 Oct 1.

  73. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
    He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL, Zhang BH, Zhang JY. BMC Cancer. 2011 Nov 22;11(1):492. [Epub ahead of print]

  74. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development
    Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J, Zhang Y, Wang H, Chen J, Shen H, Hu Z. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24799. [Epub ahead of print]

  75. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region
    Kawaoka T, Aikata H, Miyaki D, Murakami E, Azakami T, Takaki S, Nagaoki Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. Hepatol Res. 2011 Nov;41(11):1126-31. doi: 10.1111/j.1872-034X.2011.00853.x.

  76. Genetic Variation of the IL-28B Promoter Affecting Gene Expression
    Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. PLoS One. 2011;6(10):e26620. Epub 2011 Oct 25.

  77. Serum HCV RNA level is not associated with insulin resistance and metabolic syndrome in chronic hepatitis C patients with genotype 1 or 2 infection
    Huang HC, Chuang CS, Hsieh YY, Chang TS, Wei KL, Shen CH, Wu CS, Tung SY. Chang Gung Med J. 2011 Sep;34(5):487-95.

  78. Management of recurrent hepatitis C infection after liver transplantation
    Limaye AR, Firpi RJ. Clin Liver Dis. 2011 Nov;15(4):845-58.

  79. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C
    Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Aliment Pharmacol Ther. 2011 Oct 28. doi: 10.1111/j.1365-2036.2011.04897.x. [Epub ahead of print]

  80. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
    Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Hepatology. 2011 Nov;54(5):1538-46. doi: 10.1002/hep.24549.

  81. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care
    Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, Dillon JF, Forrest E, Fraser A, Gillespie R, Goldberg DJ, Kennedy N, McDonald S, McLeod A, Mills PR, Morris J, Hayes P; on behalf of the Hepatitis C Clinical Database Monitoring Committee.. Hepatology. 2011 Nov;54(5):1547-1558. doi: 10.1002/hep.24561.

  82. An Italian study on health-related quality of life and fatigue in patients with chronic fatigue syndrome and patients with chronic HCV virus infection: similarities and differences
    Racciatti D, Gorgoretti V, Sepede G, Gambi F, Pizzigallo E. Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):673-81.

  83. Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin
    Arends JE, Fransen JH, Hoepelman AI, van Baarle D. Int J Antimicrob Agents. 2011 Oct 3. [Epub ahead of print]

  84. Chronic viral hepatitis and risk of lymphoid malignancies: A retrospective twelve-year population-based cohort study in Côte d'Or, France
    Proby C, Minello A, Quantin C, Jooste V, Binquet C, Hägi M, Mounier M, Benzenine E, Hillon P, Maynadié M. Dig Liver Dis. 2011 Oct 3. [Epub ahead of print]

  85. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C
    Park SH, Kim CH, Kim DJ, Suk KT, Park JH, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Park HY, Kim YB. Clin Biochem. 2011 Sep 28. [Epub ahead of print]

  86. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy
    Lee C. Arch Pharm Res. 2011 Sep;34(9):1403-7.

  87. The study of relationship between neutropenia and infection during treatment with peginterferon ? and ribavirin for chronic hepatitis C
    Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Eur J Gastroenterol Hepatol. 2011 Oct 1. [Epub ahead of print]

  88. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C
    Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, Afdhal N, Rosen HR; on behalf of the Virahep?C Study Group. Hepatology. 2011 Jul 11. doi: 10.1002/hep.24556. [Epub ahead of print]

  89. Body piercing and tattoos: a survey on young adults' knowledge of the risks and practices in body art
    Quaranta A, Napoli C, Fasano F, Montagna C, Caggiano G, Montagna MT. BMC Public Health. 2011 Oct 7;11(1):774. [Epub ahead of print]

  90. High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection
    Chattergoon MA, Levine JS, Latanich R, Osburn WO, Thomas DL, Cox AL. J Infect Dis. 2011 Oct 7. [Epub ahead of print]

  91. Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma
    Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura SI, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K. Dig Dis Sci. 2011 Oct 12. [Epub ahead of print]

  92. Retrospective Chart Review to Assess the Relationship Between Depression and Sustained Virological Response From Interferon Treatment for Hepatitis C Virus
    Wackernah RC, Lou M, Park SH. Clin Ther. 2011 Oct 7. [Epub ahead of print]

  93. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders
    Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24724. [Epub ahead of print]

  94. Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis
    Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24731. [Epub ahead of print]

  95. Upper limits of normal for alanine aminotransferase activity in the united states population
    Ruhl E, Everhart JE. Hepatology. 2011 Oct 10. doi: 10.1002/hep.24725. [Epub ahead of print]

  96. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
    Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. J Transl Med. 2011 Oct 10;9(1):171. [Epub ahead of print]

  97. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
    Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA; On behalf of the ATAHC Study Group. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24754. [Epub ahead of print]

  98. The COBAS(®) TaqMan(®) hepatitis C virus assays: automated systems for accurate and sensitive viral load quantification
    Colucci G, Knobel R. Expert Rev Mol Diagn. 2011 Nov;11(8):793-8.

  99. Notes from the field: risk factors for hepatitis C virus infections among young adults --- massachusetts, 2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Oct 28;60:1457-8.

  100. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-?2b plus ribavirin
    Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M; the Ochanomizu-Liver Conference Study Group. Antivir Ther. 2011;16(7):1081-1091.

  101. Effects of Anti-Viral Therapy and HCV Clearance on Cerebral Metabolism and Cognition
    Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, Lenkinski R, Afdhal NH. J Hepatol. 2011 Oct 22. [Epub ahead of print]

  102. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients
    Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada SI, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N. Hepatol Int. 2011 Aug 18. [Epub ahead of print]

  103. Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection
    Wiegand J, Neumann K, Böhm S, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T. Clin Infect Dis. 2011 Oct 21. [Epub ahead of print]

  104. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the HALT-C trial
    Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; The HALT-C Trial Group. Hepatology. 2011 Oct 26. doi: 10.1002/hep.24752. [Epub ahead of print]

  105. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C
    Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, Inoue T, Sakamoto M, Okada S, Enomoto N. Hepatol Int. 2011 Aug 17. [Epub ahead of print]

  106. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
    Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S. Cancer Chemother Pharmacol. 2011 Oct 28. [Epub ahead of print]

  107. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C
    Klibanov OM, Williams SH, Smith LS, Olin JL, Vickery SB. Pharmacotherapy. 2011 Oct;31(10):951-74.

  108. Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2?weeks after therapy initiation
    Tamai H, Shingaki N, Shiraki T, Tukuda H, Mori Y, Moribata K, Enomoto S, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Hepatol Res. 2011 Sep 26. doi: 10.1111/j.1872-034X.2011.00879.x. [Epub ahead of print]

  109. Conclusion: Evaluation of viral reduction at week 2 after therapy initiation is useful for predicting SVR to low-dose PEG-IFN plus ribavirin therapy.
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Oct;54(4):1127-34. doi: 10.1002/hep.24503. Epub 2011 Aug 19.

  110. Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C
    Jilg N, Chung RT. J Hepatol. 2011 Jul 22. [Epub ahead of print]

  111. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, Ray AE, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, Marcellin P. J Hepatol. 2011 Sep 24. [Epub ahead of print]

  112. Histological Versus Clinical Cirrhosis in Chronic Hepatitis C: Does Race/Ethnicity Really Matter?
    Kohla M, Iwata S, Ea R, Keyhan S, Taylor R, Yu MC, Groshen S, Bonacini M. Dig Dis Sci. 2011 Sep 24. [Epub ahead of print]

  113. Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C-Related Hepatocellular Carcinoma
    Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Aug 4. [Epub ahead of print]

  114. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD
    Boursier J, Chaigneau J, Roullier V, Lainé F, Sandrini J, Michalak S, Hubert I, Dib N, Oberti F, Bertrais S, Hunault G, Deugnier Y, Rousselet MC, Cavaro-Ménard C, Gallois Y, Aubé C, Calès P; the study group UNAM-METABOL. Eur J Gastroenterol Hepatol. 2011 Sep 7. [Epub ahead of print]

  115. Host genomics and HCV treatment response
    Clark PJ, Thompson AJ. J Gastroenterol Hepatol. 2011 Sep 14. doi: 10.1111/j.1440-1746.2011.06918.x. [Epub ahead of print]

  116. The Supplementation of Acetyl-l-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-? 2b Plus Ribavirin
    The Supplementation of Acetyl-l-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-? 2b Plus Ribavirin

  117. Rising burden of Hepatitis C Virus in Hemodialysis Patients
    Khan S, Attaullah S, Ali I, Ayaz S, Naseemullah, Khan SN, Siraj S, Khan J. Virol J. 2011 Sep 13;8(1):438. [Epub ahead of print]

  118. New therapies for hepatitis C virus infection
    Bacon BR, Khalid O. Mo Med. 2011 Jul-Aug;108(4):255-9.

  119. Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C
    Cariani E, Critelli R, Rota C, Luongo M, Trenti T, Villa E. J Virol Methods. 2011 Aug 27. [Epub ahead of print]

  120. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma
    Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. J Viral Hepat. 2011 Oct;18(10):e550-60. doi: 10.1111/j.1365-2893.2011.01468.x. Epub 2011 May 23.

  121. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response
    Floreani A, Cazzagon N, Boemo DG, Baldovin T, Baldo V, Egoue J, Antoniazzi S, Minola E. Eur J Gastroenterol Hepatol. 2011 Sep 12. [Epub ahead of print]

  122. A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms
    Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE. Psychosomatics. 2011 Sep-Oct;52(5):433-40.

  123. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
    Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M. J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.

  124. Use of HOMA-IR in hepatitis C
    Eslam M, Kawaguchi T, Del Campo JA, Sata M, Abo-Elneen Khattab M, Romero-Gomez M. J Viral Hepat. 2011 Oct;18(10):675-84. doi: 10.1111/j.1365-2893.2011.01474.x. Epub 2011 May 25.

  125. Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C
    Perzynski AT, McCormick R, Webster NJ, Blixen CE, Kanuch S, Thomas CL, Mullen KD, Dawson NV. J Stud Alcohol Drugs. 2011 Sep;72(5):787-98.

  126. Future of hepatitis C therapy: development of direct-acting antivirals
    Dore GJ, Matthews GV, Rockstroh J. Curr Opin HIV AIDS. 2011 Sep 3. [Epub ahead of print]

  127. Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: New algorithms are more precise and entirely non-invasive
    Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, Calès P; Multicentric groups from SNIFF 32, VINDIAG 7, ANRS/HC/EP23 FIBROSTAR studies. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24654. [Epub ahead of print]

  128. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation
    Coto-Llerena M, Crespo G, González P, Koutsoudakis G, Miquel R, Navasa M, Forns X, Pérez-Del-Pulgar S. J Hepatol. 2011 Aug 31. [Epub ahead of print]

  129. Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response
    Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N. Hepatology. 2011 Aug 24. doi: 10.1002/hep.24623. [Epub ahead of print]

  130. Relative performances of FibroTest, Fibroscan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Nahour G, Vaillant JC, Ratziu V, Charlotte F. J Hepatol. 2011 Aug 31. [Epub ahead of print]

  131. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study
    Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, Merat S, Malekzadeh R. PLoS One. 2011;6(8):e23830. Epub 2011 Aug 24.

  132. Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
    Kenneth E. Sherman, M.D., Ph.D., Steven L. Flamm, M.D., Nezam H. Afdhal, M.D., David R. Nelson, M.D., Mark S. Sulkowski, M.D., Gregory T. Everson, M.D., Michael W. Fried, M.D., Michael Adler, M.D., Ph.D., Hendrik W. Reesink, M.D., Ph.D., Marie Martin, Ph.D., Abdul J. Sankoh, Ph.D., Nathalie Adda, M.D., Robert S. Kauffman, M.D., Ph.D., Shelley George, M.D., Christopher I. Wright, M.D., Ph.D., and Fred Poordad, M.D. for the ILLUMINATE Study Team

  133. Staying Safe From Hepatitis C: Engaging With Multiple Priorities
    Harris M, Treloar C, Maher L. Qual Health Res. 2011 Aug 25. [Epub ahead of print]

  134. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection
    Gonzalez SA, Keeffe EB. Gastroenterol Hepatol (N Y). 2011 Jun;7(6):366-73.

  135. The cryoglobulinaemias
    Ramos-Casals M, Stone JH, Cid MC, Bosch X. Lancet. 2011 Aug 23. [Epub ahead of print]

  136. T cell responses in hepatitis C: the good, the bad and the unconventional
    Klenerman P, Thimme R. Gut. 2011 Aug 28. [Epub ahead of print]

  137. A paradigm shift in the outpatient approach to liver function tests
    Senadhi V. South Med J. 2011 Jul;104(7):521-5.

  138. Neuropsychological alterations in hepatitis C infection: The role of inflammation
    Senzolo M, Schiff S, D'Aloiso CM, Crivellin C, Cholongitas E, Burra P, Montagnese S. World J Gastroenterol. 2011 Aug 7;17(29):3369-74.

  139. Viral hepatitis C, active component, U.S. Armed Forces, 2000-2010
    Armed Forces Health Surveillance Center (AFHSC). MSMR. 2011 Aug;18(8):10-4.

  140. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3
    Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG; for the ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Gut. 2011 Aug 26. [Epub ahead of print]

  141. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy
    Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E. Dig Liver Dis. 2011 Aug 30. [Epub ahead of print]

  142. Boceprevir: A User's Guide
    Kwo PY, Zhao R. Clin Liver Dis. 2011 Aug;15(3):537-53.

  143. The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
    Membreno FE, Lawitz EJ. Clin Liver Dis. 2011 Aug;15(3):611-26.

  144. Second-wave Protease Inhibitors: Choosing an Heir
    Ciesek S, von Hahn T, Manns MP. Clin Liver Dis. 2011 Aug;15(3):597-609. Epub 2011 Jun 25.

  145. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations
    Khalid O, Bacon BR. Clin Liver Dis. 2011 Aug;15(3):573-83.

  146. Mixing and matching drugs: what makes sense?
    Welzel TM, Zeuzem S. Clin Liver Dis. 2011 Aug;15(3):657-64.

  147. Hepatitis C therapy: other players in the game
    Ahn J, Flamm SL. Clin Liver Dis. 2011 Aug;15(3):641-56.

  148. The NS5A Replication Complex Inhibitors: Difference Makers?
    Gish RG, Meanwell NA. Clin Liver Dis. 2011 Aug;15(3):627-39.

  149. Naives, nonresponders, relapsers: who is there left to treat?
    Desai AP, Reau N. Clin Liver Dis. 2011 Aug;15(3):483-95.

  150. Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus
    Hevezi PA, Tom E, Wilson K, Lambert P, Gutierrez-Reyes G, Kershenobich D, Zlotnik A. Autoimmunity. 2011 Aug 24. [Epub ahead of print]

  151. An overview of emerging therapies for the treatment of chronic hepatitis C
    Ilyas JA, Vierling JM. Clin Liver Dis. 2011 Aug;15(3):515-36.

  152. The impact of genetic variability on liver disease in the Hispanic/Latin-American population
    Lau-Corona D, Kershenobich D, Gutierrez-Reyes G. Autoimmunity. 2011 Aug 24. [Epub ahead of print]

  153. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection
    Holmes JA, Desmond PV, Thompson AJ. Clin Liver Dis. 2011 Aug;15(3):497-513.

  154. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation
    Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. World J Hepatol. 2011 Jul 27;3(7):198-204.

  155. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection
    IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection

  156. Interferon-free regimens: the near future, the likely and the not so likely
    Shiffman ML. Clin Liver Dis. 2011 Aug;15(3):665-75. Epub 2011 Jun 25.

  157. 1990-2010: two decades of interferon-based therapy
    Buti M, Esteban R. Clin Liver Dis. 2011 Aug;15(3):473-82. Epub 2011 Jun 14.

  158. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective
    McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, I D. J Manag Care Pharm. 2011 Sep;17(7):531-46.

  159. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. J Hepatol. 2011 Aug 6. [Epub ahead of print]

  160. Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September)
    Foote BC, Spooner LM, Belliveau PP. Ann Pharmacother. 2011 Aug 9. [Epub ahead of print]

  161. Increased Risk of Severe Recurrence of Hepatitis C Virus in Liver Transplant Recipients of Donation After Cardiac Death Allografts
    Hernandez-Alejandro R, Croome KP, Quan D, Mawardi M, Chandok N, Dale C, McAlister V, Levstik MA, Wall W, Marotta P. Transplantation. 2011 Aug 9. [Epub ahead of print]

  162. Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy
    Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T, Kamimura T, Wakabayashi H, Watanabe T, Matsuda Y, Aoyagi Y. Hepatogastroenterology. 2011 May-Jun;58(107-108):965-70.

  163. Realize the advance in HCV treatment, but remain cautious
    Asselah T. J Hepatol. 2011 Aug 8. [Epub ahead of print]

  164. Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C: Results From the WIN-R Trial
    Hu KQ, Freilich B, Brown RS, Brass C, Jacobson IM. J Clin Gastroenterol. 2011 Sep;45(8):720-6.

  165. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C
    Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, Zumrutdal A, Yilmaz U. Hepatogastroenterology. 2011 May-Jun;58(107-108):875-9.

  166. A cohort study to investigate hepatocellular carcinoma risk in hepatitis C patients
    Wang CH, Mo LR, Chang KK, Lin RC, Kuo JJ. Hepatogastroenterology. 2011 May-Jun;58(107-108):904-8.

  167. Hepatitis C virus and the skin
    Al-Ali J, Al-Mutari N, Ahmed el-SF. Hepatogastroenterology. 2011 May-Jun;58(107-108):880-6.

  168. Hepatorenal Syndrome: Are We Missing Some Prognostic Factors?
    Martinez MO, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Dig Dis Sci. 2011 Aug 18. [Epub ahead of print]

  169. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study
    Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N. J Gastroenterol. 2011 Aug 20. [Epub ahead of print]

  170. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection
    Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. PLoS One. 2011;6(8):e23218. Epub 2011 Aug 17.

  171. FibroTest(®) and Fibroscan(®) performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate
    Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Moussalli J, Lebray P, Thabut D, Ratziu V. Clin Res Hepatol Gastroenterol. 2011 Aug 16. [Epub ahead of print]

  172. Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use
    Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM. J Infect Dis. 2011 Sep;204(6):825-31.

  173. Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use
    Peña-Orellana M, Hernández-Viver A, Caraballo-Correa G, Albizu-García CE. J Health Care Poor Underserved. 2011;22(3):962-82.

  174. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
    Andrade LJ, Atta AM, Atta ML, Mangabeira CN, Paraná R. Braz J Infect Dis. 2011 Aug;15(4):377-81.

  175. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males
    White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Hepatology. 2011 Aug 19. doi: 10.1002/hep.24618. [Epub ahead of print]

  176. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
    D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'era A, Lampertico P, Donato MF, De Nicola S, Prati GM, de Franchis R, Colombo M. Antivir Ther. 2011;16(5):677-84.

  177. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature
    Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S. Autoimmun Rev. 2011 Jul 24. [Epub ahead of print]

  178. Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients Undergoing Interferon-? and Ribavirin Therapy: A Prospective Evaluation
    Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Am J Gastroenterol. 2011 Aug 9. doi: 10.1038/ajg.2011.252. [Epub ahead of print]

  179. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California
    Telles Dias P, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. BMC Infect Dis. 2011 Aug 2;11(1):208. [Epub ahead of print]

  180. New hepatitis C therapies in clinical development
    Vermehren J, Sarrazin C. Eur J Med Res. 2011 Jul 25;16(7):303-14.

  181. Progress toward development of a hepatitis C vaccine with broad shoulders
    Ray R. Sci Transl Med. 2011 Aug 3;3(94):94ps33.

  182. Chronic hepatitis C
    Jang JY, Chung RT. Gut Liver. 2011 Jun;5(2):117-32. Epub 2011 Jun 24.

  183. Emerging therapeutic options in hepatitis c virus infection
    Poordad F, Khungar V. Am J Manag Care. 2011 Mar;17(4 Suppl):S123-30.

  184. Role of the nurse practitioner in the management of patients with chronic hepatitis C
    Olson M, Jacobson IM. J Am Acad Nurse Pract. 2011 Aug;23(8):410-20. doi: 10.1111/j.1745-7599.2011.00603.x. Epub 2011 Mar 31.

  185. Comparative Analysis of Hepatitis C Recurrence and Fibrosis Progression Between Deceased-Donor and Living-Donor Liver Transplantation: 8-Year Longitudinal Follow-Up
    Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Transplantation. 2011 Jul 27. [Epub ahead of print]

  186. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment
    Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Int J Infect Dis. 2011 Jul 29. [Epub ahead of print]

  187. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
    Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Lancet. 2011 Jul 27. [Epub ahead of print]

  188. Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C
    Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. J Clin Virol. 2011 Jul 29. [Epub ahead of print]

  189. Pregnancy outcomes associated with viral hepatitis
    Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.

  190. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
    Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, Colin M, Glowacki F, Dharancy S, Henrion J, Hazzan M, Noel C, Mathurin P. Aliment Pharmacol Ther. 2011 Jun 20. doi: 10.1111/j.1365-2036.2011.04741.x. [Epub ahead of print]

  191. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse
    Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Eur J Gastroenterol Hepatol. 2011 Jun 17. [Epub ahead of print]

  192. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x.

  193. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin
    Larrey D, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B, Pageaux GP, Vaucher E, Arpurt JP, Boulay G, Karlova N, Daures JP; Hepatitis C Network of Languedoc Roussillon (France). Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]

  194. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance
    Watanabe T, Konishi I, Shigematsu S, Uesugi K, Joko K, Seike H, Okada S, Miyaoka H, Nakanishi S, Abe M, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00816.x. [Epub ahead of print]

  195. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
    Brunasso AM, Puntoni M, Gulia A, Massone C. Rheumatology (Oxford). 2011 Jun 20. [Epub ahead of print]

  196. Health Utilities and Psychometric Quality of Life in Patients With Early- and Late-Stage Hepatitis C Virus Infection
    Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, Krahn MD. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06813.x. [Epub ahead of print]

  197. Cholesterol and chronic hepatitis C virus infection
    Honda A, Matsuzaki Y. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00838.x. [Epub ahead of print]

  198. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
    Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N. J Gastroenterol. 2011 Jun 17. [Epub ahead of print]

  199. Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. N Engl J Med. 2011 Jun 23;364(25):2405-16.

  200. Telaprevir for retreatment of HCV infection
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. N Engl J Med. 2011 Jun 23;364(25):2417-28.

  201. Viral hepatitis: Impact of adherence to combination therapy for hepatitis C
    Arase Y. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):248-9.

  202. Telaprevir Alone or with Peginterferon and Ribavirin Reduces HCV RNA in Patients with Chronic Genotype 2 but Not 3 Infections
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Gastroenterology. 2011 May 31. [Epub ahead of print]

  203. Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses
    Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]

  204. Acute hepatitis C infection lowers serum lipid levels
    Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, Lauer GM, Chung RT. J Viral Hepat. 2011 Jul;18(7):e366-71. doi: 10.1111/j.1365-2893.2011.01434.x. Epub 2011 Feb 8.

  205. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1
    Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A. J Viral Hepat. 2011 Jul;18(7):e372-80. doi: 10.1111/j.1365-2893.2011.01439.x. Epub 2011 Feb 22.

  206. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis
    Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.

  207. Improving surveillance for acute hepatitis C
    Deacon RM, Wand H, Stelzer-Braid S, Treloar C, Maher L. Commun Dis Intell. 2011 Mar;35(1):16-20.

  208. The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C
    Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC; for the Veterans Aging Cohort Study. Circ Cardiovasc Qual Outcomes. 2011 Jun 28. [Epub ahead of print]

  209. Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P. BMC Res Notes. 2011 Jun 29;4(1):220. [Epub ahead of print]

  210. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK. Dig Dis Sci. 2011 Jun 25. [Epub ahead of print]

  211. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML. J Hepatol. 2011 May 19. [Epub ahead of print]

  212. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Jun 30. doi: 10.1002/hep.24503. [Epub ahead of print]

  213. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. J Hepatol. 2011 Apr 14. [Epub ahead of print]

  214. Ophthalmological complications in hepatitis C virus infection: Side effect of interferon therapy or a direct role of HCV?
    Pazienza V. Biomed Pharmacother. 2011 May 30. [Epub ahead of print]

  215. Oral combination therapy: Future hepatitis C virus treatment?
    Hézode C. J Hepatol. 2011 May 19. [Epub ahead of print]

  216. Efficacy and Safety of Pegylated Interferon in Children and adolescents Infected with Chronic Hepatitis C: A Preliminary Study
    Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. J Pharm Pract. 2011 Apr;24(2):203-10. Epub 2010 Apr 2.

  217. A sprint to increase response to HCV treatment: expectancies but caution
    Asselah T. J Hepatol. 2011 Jun 30. [Epub ahead of print]

  218. The tasks of self-managing hepatitis C: The significance of disclosure
    Fry M, Bates G. Psychol Health. 2011 Jul 7. [Epub ahead of print]

  219. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease
    Peres WA, Chaves GV, Gonçalves JC, Ramalho A, Coelho HS. Br J Nutr. 2011 Jun 8:1-8. [Epub ahead of print]

  220. Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature
    Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Clin Lymphoma Myeloma Leuk. 2011 May 12. [Epub ahead of print]

  221. Spontaneous clearance of hepatitis C virus in vertically infected children
    Farmand S, Wirth S, Löffler H, Woltering T, Kenzel S, Lainka E, Henneke P. Eur J Pediatr. 2011 Jul 7. [Epub ahead of print]

  222. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes
    Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ. Liver Int. 2011 Aug;31(7):1028-38. doi: 10.1111/j.1478-3231.2011.02549.x. Epub 2011 May 25.

  223. Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data
    Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA. J Gastroenterol Hepatol. 2011 Jul 1. doi: 10.1111/j.1440-1746.2011.06834.x. [Epub ahead of print]

  224. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene
    Toyoda H, Kumada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F. J Med Virol. 2011 Sep;83(9):1559-64. doi: 10.1002/jmv.22145.

  225. Insulin resistance and chronic liver disease
    Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, Sata M. World J Hepatol. 2011 May 27;3(5):99-107.

  226. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes
    Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Liver Int. 2011 Jun 7. doi: 10.1111/j.1478-3231.2011.02556.x. [Epub ahead of print]

  227. Hepatitis C virus infection in USA: an estimate of true prevalence
    Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Liver Int. 2011 Mar 16. doi: 10.1111/j.1478-3231.2011.02494.x. [Epub ahead of print]

  228. An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C
    O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; and the HALT-C Trial Group. PLoS One. 2011;6(7):e20904. Epub 2011 Jul 8.

  229. Gaps in the Achievement of Effectiveness of HCV Treatment in National VA Practice
    Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag H, Kramerer JR. J Hepatol. 2011 Jul 11. [Epub ahead of print]

  230. Diagnosing and treating hepatitis c virus infection
    Schiff ER. Am J Manag Care. 2011 Mar;17(4 Suppl):S108-15.

  231. Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C
    Burgueño-Montañés C, Pérez-Álvarez R. Arch Soc Esp Oftalmol. 2011 Jun;86(6):193-195. Epub 2011 Apr 29.

  232. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse
    Lan CL, Guillygomarc'h A, Danielou H, Dréau GL, Lainé F, Védeilhié C, Deugnier Y, Brissot P, Guyader D, Moirand R. J Hepatol. 2011 Jul 11. [Epub ahead of print]

  233. Improved Responses to Pegylated Interferon alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks
    Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Gastroenterology. 2011 Jul 21. [Epub ahead of print]

  234. Peginterferon Maintenance Therapy in Patients with Advanced Hepatitis C to Prevent Hepatocellular Carcinoma: The Plot Thickens
    Aghemo A, Colombo M. J Hepatol. 2011 Jul 20. [Epub ahead of print]

  235. Current understanding of insulin resistance in hepatitis C
    Kaddai V, Negro F. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):503-16.

  236. Mechanisms of non-response to antiviral treatment in chronic hepatitis C
    Chevaliez S, Asselah T. Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S31-41.

  237. Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus
    Brandman D, Pingitore A, Lai J, Roberts J, Ferrell L, Bass N, Terrault N. Liver Transpl. 2011 Jul 18. doi: 10.1002/lt.22389. [Epub ahead of print]

  238. Liver stiffness diminishes with antiviral response in chronic hepatitis C
    Hézode C, Castéra L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, Leroy V, Mallat A, Pawlotsky JM. Aliment Pharmacol Ther. 2011 Jul 13. doi: 10.1111/j.1365-2036.2011.04765.x. [Epub ahead of print]

  239. Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study
    Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ, Pereira LM, Alvares-da-Silva MR. Int J Cardiol. 2011 Jul 22. [Epub ahead of print]

  240. Hyporesponsiveness to pegifn?2b plus ribavirin in patients with hepatitis C-related advanced fibrosis
    Prati GM, Aghemo A, Rumi MG, D'Ambrosio R, Nicola SD, Donato MF, Degasperi E, Colombo M. J Hepatol. 2011 Jul 11. [Epub ahead of print]

  241. A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment
    Evon DM, Simpson K, Kixmiller S, Galanko J, Dougherty K, Golin C, Fried MW. Am J Gastroenterol. 2011 Jul 19. doi: 10.1038/ajg.2011.219. [Epub ahead of print]

  242. Pregnancy outcomes associated with viral hepatitis
    Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. J Viral Hepat. 2011 Jul;18(7):e394-8. doi: 10.1111/j.1365-2893.2011.01436.x. Epub 2011 Feb 8.

  243. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
    Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, Colin M, Glowacki F, Dharancy S, Henrion J, Hazzan M, Noel C, Mathurin P. Aliment Pharmacol Ther. 2011 Jun 20. doi: 10.1111/j.1365-2036.2011.04741.x. [Epub ahead of print]

  244. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse
    Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Eur J Gastroenterol Hepatol. 2011 Jun 17. [Epub ahead of print]

  245. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
    Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x.

  246. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alfa2a and Ribavirin
    Larrey D, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B, Pageaux GP, Vaucher E, Arpurt JP, Boulay G, Karlova N, Daures JP; Hepatitis C Network of Languedoc Roussillon (France). Clin Gastroenterol Hepatol. 2011 Jun 6. [Epub ahead of print]

  247. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance
    Watanabe T, Konishi I, Shigematsu S, Uesugi K, Joko K, Seike H, Okada S, Miyaoka H, Nakanishi S, Abe M, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00816.x. [Epub ahead of print]

  248. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review
    Brunasso AM, Puntoni M, Gulia A, Massone C. Rheumatology (Oxford). 2011 Jun 20. [Epub ahead of print]

  249. Health Utilities and Psychometric Quality of Life in Patients With Early- and Late-Stage Hepatitis C Virus Infection
    Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, Weiss AA, Krahn MD. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06813.x. [Epub ahead of print]

  250. Cholesterol and chronic hepatitis C virus infection
    Honda A, Matsuzaki Y. Hepatol Res. 2011 Jun 17. doi: 10.1111/j.1872-034X.2011.00838.x. [Epub ahead of print]

  251. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
    Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N. J Gastroenterol. 2011 Jun 17. [Epub ahead of print]

  252. Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. N Engl J Med. 2011 Jun 23;364(25):2405-16.

  253. Telaprevir for retreatment of HCV infection
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. N Engl J Med. 2011 Jun 23;364(25):2417-28.

  254. Viral hepatitis: Impact of adherence to combination therapy for hepatitis C
    Arase Y. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):248-9.

  255. Telaprevir Alone or with Peginterferon and Ribavirin Reduces HCV RNA in Patients with Chronic Genotype 2 but Not 3 Infections
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Gastroenterology. 2011 May 31. [Epub ahead of print]

  256. Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses
    Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M. Hepatol Res. 2011 Jun 23. doi: 10.1111/j.1872-034X.2011.00843.x. [Epub ahead of print]

  257. Acute hepatitis C infection lowers serum lipid levels
    Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, Lauer GM, Chung RT. J Viral Hepat. 2011 Jul;18(7):e366-71. doi: 10.1111/j.1365-2893.2011.01434.x. Epub 2011 Feb 8.

  258. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1
    Petta S, Di Marco V, Di Stefano R, Cabibi D, Cammà C, Marchesini G, Craxì A. J Viral Hepat. 2011 Jul;18(7):e372-80. doi: 10.1111/j.1365-2893.2011.01439.x. Epub 2011 Feb 22.

  259. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis
    Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):285-95.

  260. Improving surveillance for acute hepatitis C
    Deacon RM, Wand H, Stelzer-Braid S, Treloar C, Maher L. Commun Dis Intell. 2011 Mar;35(1):16-20.

  261. The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C
    Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC; for the Veterans Aging Cohort Study. Circ Cardiovasc Qual Outcomes. 2011 Jun 28. [Epub ahead of print]

  262. Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Maieron A, Metz-Gercek S, Scherzer TM, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P. BMC Res Notes. 2011 Jun 29;4(1):220. [Epub ahead of print]

  263. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK. Dig Dis Sci. 2011 Jun 25. [Epub ahead of print]

  264. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML. J Hepatol. 2011 May 19. [Epub ahead of print]

  265. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Hepatology. 2011 Jun 30. doi: 10.1002/hep.24503. [Epub ahead of print]

  266. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. J Hepatol. 2011 Apr 14. [Epub ahead of print]

  267. Ophthalmological complications in hepatitis C virus infection: Side effect of interferon therapy or a direct role of HCV?
    Pazienza V. Biomed Pharmacother. 2011 May 30. [Epub ahead of print]

  268. Oral combination therapy: Future hepatitis C virus treatment?
    Hézode C. J Hepatol. 2011 May 19. [Epub ahead of print]

  269. Efficacy and Safety of Pegylated Interferon in Children and adolescents Infected with Chronic Hepatitis C: A Preliminary Study
    Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. J Pharm Pract. 2011 Apr;24(2):203-10. Epub 2010 Apr 2.

  270. Risk factors for the development of depression in patients with hepatitis C taking interferon-?
    Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Neuropsychiatr Dis Treat. 2011;7:275-92. Epub 2011 May 15.

  271. Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3.
    Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM, McHutchison JG, Sulkowski MS, Zeuzem S, Nelson DR. Clin Gastroenterol Hepatol. 2011 May 13. [Epub ahead of print]

  272. All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population
    El-Kamary SS, Jhaveri R, Shardell MD. Clin Infect Dis. 2011 Jun 10. [Epub ahead of print]

  273. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized controlled trials and implications for the future
    Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, Buti M, Sheppard F, Ferenci P, Thévenot T. Hepatology. 2011 Jun 14. doi: 10.1002/hep.24480. [Epub ahead of print]

  274. Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin
    de Rueda PM, López-Nevot MA, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, Gila A, Romero-Gómez M, Pavón EJ, Muñoz JA, Carazo A, Sanz-Cameno P, Moreno-Otero R, Diago M, León J, Ruiz-Extremera A, Salmerón J. Am J Gastroenterol. 2011 Jun 14. doi: 10.1038/ajg.2011.82. [Epub ahead of print]

  275. Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?
    Peltekian KM, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Balshaw R, Deschênes M. Ann Hepatol. 2011 Jun 1;10(3):260-9.

  276. Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study
    ReViS-TC Study Group. Transplantation. 2011 Jun 8. [Epub ahead of print]

  277. Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome
    Miyaaki H, Ichikawa T, Taura N, Miuma S, Shibata H, Isomoto H, Takeshima F, Nakao K. Intern Med. 2011;50(11):1137-41. Epub 2011 Jun 1.

  278. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C
    Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H. J Infect Dis. 2011 Jul;204(1):84-93.

  279. Meta-analysis: insulin resistance and sustained virological response in hepatitis C
    Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Aliment Pharmacol Ther. 2011 May 29. doi: 10.1111/j.1365-2036.2011.04716.x. [Epub ahead of print]

  280. Unmet needs among people reported with hepatitis C, new york city
    Bornschlegel K, Crotty KJ, Sahl S, Balter S. J Public Health Manag Pract. 2011 Jul-Aug;17(4):E9-E17.

  281. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. N Engl J Med. 2011 Jun 1. [Epub ahead of print]

  282. Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study
    Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A. Dig Dis Sci. 2011 Jun 2. [Epub ahead of print]

  283. Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin
    Garib JR, Garcia GF, Teixeira R, Lima E Silva FD. Scand J Infect Dis. 2011 May 2. [Epub ahead of print]

  284. Host-based ribavirin resistance influences hepatitis C virus replication and treatment response
    Ibarra KD, Jain MK, Pfeiffer JK. J Virol. 2011 May 4. [Epub ahead of print]

  285. Hepatitis C virus infected females have a higher risk of advanced fibrosis and graft loss after liver transplantation than males
    Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA; for the ConsoRtiUm to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatology. 2011 Apr 28. doi: 10.1002/hep.24390. [Epub ahead of print]

  286. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection
    Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A. Eur J Clin Invest. 2011 Mar 9. doi: 10.1111/j.1365-2362.2011.02498.x. [Epub ahead of print]

  287. Understanding the host genetics of chronic hepatitis B and C
    Thursz M, Yee L, Khakoo S. Semin Liver Dis. 2011 May;31(2):115-27. Epub 2011 May 2.

  288. Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: A vicious circle of clinical significance?
    Franceschini L, Realdon S, Marcolongo M, Mirandola S, Bortoletto G, Alberti A. Hepatology. 2011 Apr 29. doi: 10.1002/hep.24394. [Epub ahead of print]

  289. Hepatitis C virus infection among adolescents and young adults --- massachusetts, 2002--2009
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41.

  290. Hepatitis C-related cirrhosis with sustained prevention of hepatocellular carcinoma recurrence by long-term administration of super-low-dose peginterferon-alpha 2b
    Mamori S, Mamori H. Case Rep Gastroenterol. 2011 Jan 19;5(1):56-62.

  291. Racial differences in hepatitis C treatment eligibility
    Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; on behalf of the IDEAL Study Team. Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358. [Epub ahead of print]

  292. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (HEP-10-2210)
    Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; for the HALT-C Trial Group. Hepatology. 2011 Apr 21. doi: 10.1002/hep.24370.

  293. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C
    Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E; and the Nagano Interferon Treatment Research Group. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00802.x. [Epub ahead of print]

  294. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus
    Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR; for the PHOENIX Study Group. Liver Transpl. 2011 May;17(5):528-538. doi: 10.1002/lt.22271.

  295. Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection
    Huang JF, Chuang YH, Dai CY, Yu ML, Huang CF, Hsiao PJ, Hsieh MY, Huang CI, Yeh ML, Yang JF, Lin ZY, Chen SC, Chuang WL. Hepatol Res. 2011 Apr 19. doi: 10.1111/j.1872-034X.2011.00786.x. [Epub ahead of print]

  296. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin
    Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM. AIDS. 2011 Apr 18. [Epub ahead of print]

  297. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination
    Ohara T, Oteki T, Suzuki T, Suzuki M, Matsuzaki Y. Hepatogastroenterology. 2011 Jan-Feb;58(105):133-6.

  298. The dissociation between the diabetes and both Child-Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic
    Chen YW, Chen HH, Wang TE, Chang CW, Chang CW, Chen WC, Wu CJ. Hepatol Int. 2011 Apr 21. [Epub ahead of print]

  299. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy
    Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K. J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.

  300. IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection
    Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS. PLoS One. 2011 Mar 30;6(3):e18322.

  301. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)
    Imhof I, Simmonds P. Hepatology. 2011 Apr;53(4):1090-9. doi: 10.1002/hep.24172.

  302. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon
    Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; for the HALT-C Trial Group. Hepatology. 2011 Apr;53(4):1100-1108. doi: 10.1002/hep.24169.

  303. Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?
    Carrion AF, Fabrizi F, Martin P. Semin Dial. 2011 Apr 11. doi: 10.1111/j.1525-139X.2011.00851.x. [Epub ahead of print]

  304. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1
    Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; on behalf of the CHARIOT Study Group. Hepatology. 2011 Apr;53(4):1109-1117. doi: 10.1002/hep.24180.

  305. Frequency of HCV infection in renal cell carcinoma patients
    Budako?lu B, Aksoy S, Arslan C, Uyetürk U, Babacan NA, Ozcan MF, Y?ld?z R, Oven BB, Ozdemir NY, Dizdar O, Büyükberber S, Ak?nc? MB, Türker I, Oksüzo?lu B, Altundag K, Zengin N. Med Oncol. 2011 Apr 3. [Epub ahead of print]

  306. Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review)
    Grüngreiff K, Reinhold D. Mol Med Report. 2010 May-Jun;3(3):371-5. doi: 10.3892/mmr_00000267.

  307. A new standard of care for the treatment of chronic HCV infection
    Hofmann WP, Zeuzem S. Nat Rev Gastroenterol Hepatol. 2011 Apr 5. [Epub ahead of print]

  308. Hepatitis C virus NS3/4A protease quasispecies complexity and catalytic efficiency influence responsiveness to peginterferon plus ribavirin treatment in HCV/HIV-co-infected patients
    Aparicio E, Franco S, Parera M, Andrés C, Tural C, Clotet B, Martínez MA. J Virol. 2011 Apr 6. [Epub ahead of print]

  309. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus
    Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D. J Viral Hepat. 2011 May;18(5):305-15. doi: 10.1111/j.1365-2893.2011.01451.x. Epub 2011 Mar 23

  310. A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C
    Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, Oberti F, Dib N, Calès P. Am J Gastroenterol. 2011 Apr 5. [Epub ahead of print]

  311. Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation
    Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, Navasa M, Forns X. Am J Transplant. 2011 Apr 5. doi: 10.1111/j.1600-6143.2011.03491.x. [Epub ahead of print]

  312. Differences in circulating MMP-9 levels with regard to viral load and AST:ALT ratio between chronic hepatitis B and C patients
    Helaly GF. Br J Biomed Sci. 2011;68(1):38-42.

  313. Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes
    Fernandez-Rodriguez CM, Gutierrez ML, Lledó JL, Casas ML. World J Gastroenterol. 2011 Mar 28;17(12):1558-62.

  314. Occult hepatitis B virus infection: A complex entity with relevant clinical implications
    Larrubia JR. World J Gastroenterol. 2011 Mar 28;17(12):1529-30.

  315. Host genetics in immune-mediated hepatitis C virus clearance
    Schmidt J, Thimme R, Neumann-Haefelin C. Biomark Med. 2011 Apr;5(2):155-69.

  316. Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey
    Marconi A, Candido S, Talamini R, Libra M, Nicoletti F, Spandidos DA, Stivala F, Proietti L. Mol Med Report. 2010 Jul-Aug;3(4):561-4. doi: 10.3892/mmr_00000297.

  317. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
    Hartwell D, Jones J, Baxter L, Shepherd J. Health Technol Assess. 2011 Apr;15(17):1-210.

  318. Clinical significance of occult hepatitis B virus infection
    Romero M, Madejón A, Fernández-Rodríguez C, García-Samaniego J. World J Gastroenterol. 2011 Mar 28;17(12):1549-52.

  319. Malnutrion Impairs Interferon Signaling through mTOR and FoxO pathways in Patients with Chronic Hepatitis C
    Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2011 Mar 30. [Epub ahead of print]

  320. Genetics in liver disease: new concepts
    Zimmer V, Lammert F. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]

  321. A new era of hepatitis C therapy begins
    Jensen DM. N Engl J Med. 2011 Mar 31;364(13):1272-4.

  322. Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression
    Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG. Gastroenterol Nurs. 2011 March/April;34(2):102-106.

  323. Acoustic Liver Biopsy in Patients with Hepatitis C and Advanced Liver Fibrosis Using Endoscopic Ultrasound
    Vegesna A, Nazir A, Chung CY, Kane S, Thomas R, Miller L. Dig Dis Sci. 2011 Apr 1. [Epub ahead of print]

  324. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis
    Chen JJ, Yu CB, Du WB, Li LJ. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):122-7.

  325. Delayed viral clearance of chronic hepatitis C in patients after treatment failure
    Cho SH, Lee SW, Choi SR, Han SY, Roh MH, Lee JH, Jang JS, Baek YH, Kim SY. Gut Liver. 2011 Mar;5(1):110-4. Epub 2011 Mar 16.

  326. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2011 Mar 24. [Epub ahead of print]

  327. Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma
    Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC. Gut Liver. 2011 Mar;5(1):77-81. Epub 2011 Mar 16.

  328. High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial)
    Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Gastroenterology. 2011 Mar 23. [Epub ahead of print]

  329. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C
    Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; on behalf of the ITAHEC Study Group. Aliment Pharmacol Ther. 2011 Mar 28. doi: 10.1111/j.1365-2036.2011.04635.x. [Epub ahead of print]

  330. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment
    Irshad M, Ansari MA, Singh A, Nag P, Raghvendra L, Singh S, Badhal SS. Hepatogastroenterology. 2010 Nov-Dec;57(104):1529-38.

  331. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States from 1988-2008
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Clin Gastroenterol Hepatol. 2011 Mar 24. [Epub ahead of print]

  332. Hepatic encephalopathy: A central neuroinflammatory disorder?
    Butterworth RF. Hepatology. 2011 Apr;53(4):1372-6. doi: 10.1002/hep.24228.

  333. Increased risk of parkinsonism among patients with cirrhosis: a 7-year follow-up study
    Kang JH, Tsai MC, Lin CC, Lin HL, Lin HC. Liver Int. 2011 May;31(5):685-691. doi: 10.1111/j.1478-3231.2010.02432.x. Epub 2011 Jan 11.

  334. Validation of the Psychometric Hepatic Encephalopathy Score (PHES) for Identifying Patients with Minimal Hepatic Encephalopathy
    Duarte-Rojo A, Estradas J, Hernández-Ramos R, Ponce-de-León S, Córdoba J, Torre A. Dig Dis Sci. 2011 Apr 3. [Epub ahead of print]

  335. Regional variations in the concentrations of ketone bodies in cirrhosis and hepatic encephalopathy: a study in patients with TIPSS
    Dabos KJ, Houghton BJ, Pyleris E, Redhead DN, Hayes PC, Salder IH, Plevris JN. Liver Int. 2011 May;31(5):707-11. doi: 10.1111/j.1478-3231.2011.02483.x. Epub 2011 Mar 6.

  336. Microglia activation in hepatic encephalopathy
    Zemtsova I, Görg B, Keitel V, Bidmon HJ, Schrör K, Häussinger D. Hepatology. 2011 Mar 30. doi: 10.1002/hep.24326. [Epub ahead of print]

  337. Complications and outcomes in chronic liver disease
    Rahimi RS, Rockey DC. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]

  338. Low-protein diets for hepatic encephalopathy debunked: let them eat steak
    Cabral CM, Burns DL. Nutr Clin Pract. 2011 Apr;26(2):155-9.

  339. Management of Hepatitis C Antiviral Therapy Adverse Effects
    Sung H, Chang M, Saab S. Curr Hepat Rep. 2011 Mar;10(1):33-40. Epub 2010 Dec 24.

  340. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more
    Pearlman BL, Traub N. Clin Infect Dis. 2011 Apr;52(7):889-900.

  341. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?
    Vezali E, Aghemo A, Lampertico P, Colombo M. Clin Res Hepatol Gastroenterol. 2011 Mar 22. [Epub ahead of print]

  342. Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C
    Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC(3) Study Group. Gastroenterology. 2011 Mar 16. [Epub ahead of print]

  343. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease
    Gisbert JP, Chaparro M, Esteve M. Aliment Pharmacol Ther. 2011 Mar;33(6):619-33.

  344. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection
    Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]

  345. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
    Fred Poordad, M.D., Jonathan McCone, Jr., M.D., Bruce R. Bacon, M.D., Savino Bruno, M.D., Michael P. Manns, M.D., Mark S. Sulkowski, M.D., Ira M. Jacobson, M.D., K. Rajender Reddy, M.D., Zachary D. Goodman, M.D., Ph.D., Navdeep Boparai, M.S., Mark J. DiNubile, M.D., Vilma Sniukiene, M.D., Clifford A. Brass, M.D., Ph.D., Janice K. Albrecht, Ph.D., and Jean-Pierre Bronowicki, M.D., Ph.D. for the SPRINT-2 Investigators. N Engl J Med 2011; 364:1195-1206March 31, 2011

  346. Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States from 1988-2008
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Clin Gastroenterol Hepatol. 2011 Mar 24. [Epub ahead of print]

  347. Gastroenterology. 2011 Mar 24. [Epub ahead of print]
    A Functional Polymorphism in the Epidermal Growth Factor Gene is Associated with Risk for Hepatocellular Carcinoma.

  348. High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial)
    Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Gastroenterology. 2011 Mar 23. [Epub ahead of print]

  349. Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma
    Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC. Gut Liver. 2011 Mar;5(1):77-81. Epub 2011 Mar 16.

  350. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
    Lange CM, Zeuzem S. J Hepatol. 2011 Mar 24. [Epub ahead of print]

  351. Delayed viral clearance of chronic hepatitis C in patients after treatment failure
    Cho SH, Lee SW, Choi SR, Han SY, Roh MH, Lee JH, Jang JS, Baek YH, Kim SY. Gut Liver. 2011 Mar;5(1):110-4. Epub 2011 Mar 16.

  352. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis
    Chen JJ, Yu CB, Du WB, Li LJ. Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):122-7.

  353. Acoustic Liver Biopsy in Patients with Hepatitis C and Advanced Liver Fibrosis Using Endoscopic Ultrasound
    Vegesna A, Nazir A, Chung CY, Kane S, Thomas R, Miller L. Dig Dis Sci. 2011 Apr 1. [Epub ahead of print]

  354. Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression
    Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG. Gastroenterol Nurs. 2011 March/April;34(2):102-106.

  355. A new era of hepatitis C therapy begins
    Jensen DM. N Engl J Med. 2011 Mar 31;364(13):1272-4.

  356. Genetics in liver disease: new concepts
    Zimmer V, Lammert F. Curr Opin Gastroenterol. 2011 Mar 30. [Epub ahead of print]

  357. Malnutrion Impairs Interferon Signaling through mTOR and FoxO pathways in Patients with Chronic Hepatitis C
    Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2011 Mar 30. [Epub ahead of print]

  358. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection
    Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Hepatology. 2011 Mar 21. doi: 10.1002/hep.24308. [Epub ahead of print]

  359. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials
    D'Heygere F, George C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M, Delwaide J, Laureys A, Nevens F. J Med Virol. 2011 May;83(5):815-9. doi: 10.1002/jmv.22049.

  360. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection
    Petta S, Cammà C, Marco VD, Macaluso FS, Maida M, Pizzolanti G, Belmonte B, Cabibi D, Stefano RD, Ferraro D, Guarnotta C, Venezia G, Craxì A. Liver Int. 2011 Apr;31(4):507-15.

  361. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment
    Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Liver Int. 2011 Apr;31(4):443-60.

  362. Hepatitis C virus in primary care: survey of nurses' attitudes to caring
    Frazer K, Glacken M, Coughlan B, Staines A, Daly L. J Adv Nurs. 2011 Mar;67(3):598-608.

  363. Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
    Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Dig Dis Sci. 2011 Mar 5. [Epub ahead of print]

  364. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 Mar 3.. [Epub ahead of print]

  365. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus
    Pawlotsky JM. Hepatology. 2011 Mar 3. doi: 10.1002/hep.24262. [Epub ahead of print]

  366. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.

  367. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
    Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Nat Rev Gastroenterol Hepatol. 2011 Mar 8. [Epub ahead of print]

  368. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities
    Dibonaventura MD, Wagner JS, Yuan Y, L'italien G, Langley P, Ray Kim W. J Med Econ. 2011 Mar 9. [Epub ahead of print]

  369. Second phase HCV RNA decline during telaprevir based therapy increases with drug effectiveness: Implications for treatment duration
    Guedj J, Perelson AS. Hepatology. 2011 Mar 7. [Epub ahead of print]

  370. Coffee Consumption is Associated with Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C
    Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group. Gastroenterology. 2011 Mar 1. [Epub ahead of print]

  371. Depression in patients with nonalcoholic Fatty liver disease and chronic viral hepatitis B and C
    Weinstein AA, Kallman Price J, Stepanova M, Poms LW, Fang Y, Moon J, Nader F, Younossi ZM. Psychosomatics. 2011 Mar-Apr;52(2):127-32.

  372. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation
    Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M. Liver Transpl. 2011 Mar;17(3):289-98.

  373. IL-32: A new proinflammatory cytokine involved in HCV-related liver inflammation and fibrosis
    Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R, Jonsson JR, Tilg H. Hepatology. 2011 Mar 4. doi: 10.1002/hep.24285. [Epub ahead of print]

  374. Survival After Liver Transplantation Using Hepatitis C Virus-Positive Donor Allografts: Case-Controlled Analysis of the UNOS Database
    Burr AT, Li Y, Tseng JF, Saidi RF, Bozorgzadeh A, Shah SA. World J Surg. 2011 Mar 8. [Epub ahead of print]

  375. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
    Neukam K, Nattermann J, Rallón N, Rivero A, Caruz A, Macías J, Vogel M, Benito J, Camacho A, Mira J, Schwarze-Zander C, Barreiro P, Martínez A, Rockstroh J, Soriano V, Pineda J. HIV Med. 2011 Mar 6. [Epub ahead of print]

  376. HCV RNA decline in the first 24hours exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin
    Laufer N, Bolcic F, Rolón M, Martinez A, Reynoso R, Pérez H, Salomón H, Cahn P, Quarleri J. Antiviral Res. 2011 Mar 1. [Epub ahead of print]

  377. A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients with Hepatitis C
    Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. Clin Gastroenterol Hepatol. 2011 Mar 10. [Epub ahead of print]

  378. Non-Invasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C
    Vergniol J, Foucher J, Terrebonne E, Bernard PH, Le Bail B, Merrouche W, Couzigou P, de Lédinghen V. Gastroenterology. 2011 Mar 1. [Epub ahead of print]

  379. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients
    Patel K, Lucas J, Thompson J, Dubois L, Tillmann H, Thompson A, Uzarski D, Califf R, Moseley M, Ginsburg G, McHutchison J, McCarthy J; for MURDOCK Horizon 1 Study Team. Hepatology. 2011 Mar 4. [Epub ahead of print]

  380. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients
    Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; on behalf of CoRIS. AIDS. 2011 Mar 3. [Epub ahead of print]

  381. Insulin Resistance is Independently Associated with Significant Hepatic Fibrosis in Asian Chronic Hepatitis C Genotype 2 or 3 Patients
    Patel K, Thompson A, Chuang W, Lee C, Peng C, Shanmuganathan G, Thongsawat S, Tanwandee T, Mahachai V, Pramoolsinsap C, Cho M, Han K, Shah S, Foster G, Clark P, Pulkstenis E, Subramanian M, McHutchison J. J Gastroenterol Hepatol. 2011 Mar 16. doi: 10.1111/j.1440-1746.2011.06722.x. [Epub ahead of print]

  382. Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children
    Ruiz-Extremera A, Muñoz-Gámez J, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Martín AB, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J. Hepatology. 2011 Mar 16. [Epub ahead of print]

  383. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort
    Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, Kneteman N, Mills EJ. AIDS. 2011 Mar 27;25(6):777-86.

  384. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study
    Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, Lang JP, Melin P, Cacoub P; for the CheObs Study Group. Liver Int. 2011 Apr;31(4):516-524.Epub 2011 Feb 15.

  385. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C
    Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. J Hepatol. 2011 Jan 12. [Epub ahead of print]

  386. New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Asselah T, Marcellin P. Liver Int. 2011 Jan;31 Suppl 1:68-77.

  387. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
    Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. J Gastroenterol. 2011 Jan 19. [Epub ahead of print]

  388. Impact of a sustained virological response on the long-term outcome of hepatitis C
    Alberti A. Liver Int. 2011 Jan;31 Suppl 1:18-22.

  389. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients
    Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. World J Gastroenterol. 2011 Feb 21;17(7):914-21.

  390. Hepatitis C virus infection during pregnancy and the newborn period - are they opportunities for treatment?
    Arshad M, El-Kamary SS, Jhaveri R. J Viral Hepat. 2011 Apr;18(4):229-36. doi: 10.1111/j.1365-2893.2010.01413.x. Epub 2011 Jan 7.

  391. How to use virological tools for the optimal management of chronic hepatitis C
    de Leuw P, Sarrazin C, Zeuzem S. Liver Int. 2011 Jan;31 Suppl 1:3-12.

  392. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?
    Castera L, Bedossa P. Liver Int. 2011 Jan;31 Suppl 1:13-7.

  393. Future hepatitis C virus treatment: interferon-sparing combinations
    Gane E. Liver Int. 2011 Jan;31 Suppl 1:62-7.

  394. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    McHutchison JG. Liver Int. 2011 Jan;31 Suppl 1:29-35.

  395. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients
    Petta S, Craxì A. Liver Int. 2011 Jan;31 Suppl 1:36-44.

  396. Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis
    Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group. J Hepatol. 2011 Jan 11. [Epub ahead of print]

  397. Sustained virologic response among Latino veterans; does it represent the cure of chronic hepatitis C infection?
    De Jesús J, Nieves-Santiago P, Rodríguez-Pérez F, Toro DH. P R Health Sci J. 2010 Dec;29(4):397-401.

  398. Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic Hepatitis C patients
    de Almeida CM, de Lima TA, Castro DB, Torres KL, da Silva Braga W, Peruhype-Magalhães V, Teixeira-Carvalho A, Martins-Filho OA, Malheiro A. Scand J Immunol. 2011 Jan 13. [Epub ahead of print]

  399. Treatment of hepatitis C virus infection in patients with end-stage renal disease
    Liu CH, Kao JH. J Gastroenterol Hepatol. 2011 Feb;26(2):228-39.

  400. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
    Jamma S, Hussain G, Lau DT. Curr Hepat Rep. 2010;9(4):260-269.

  401. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads
    Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Hepatol Res. 2011 Feb;41(2):126-32.

  402. Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study
    Gamage DG, Read TR, Bradshaw CS, Hocking JS, Howley K, Chen MY, Fairley CK. BMC Infect Dis. 2011 Feb 3;11(1):39. [Epub ahead of print]

  403. Hepatitis C virus Resistance to Protease Inhibitors
    Halfon P, Locarnini S. J Hepatol. 2011 Jan 29. [Epub ahead of print]

  404. Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C
    Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 Feb 2. [Epub ahead of print]

  405. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin
    Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. World J Gastroenterol. 2011 Jan 28;17(4):493-8.

  406. Interferon lambdas: the next cytokine storm
    Kelly C, Klenerman P, Barnes E. Gut. 2011 Feb 8. [Epub ahead of print]

  407. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease
    Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 Feb 8. [Epub ahead of print]

  408. Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men
    Fierer DS. Curr Infect Dis Rep. 2010 Mar;12(2):118-25.

  409. Recommendations for the management of mixed Cryoglobulinemia syndrome in Hepatitis C virus-infected patients
    Pietrogrande M, Devita S, Zignego A, et al. Autoimmun Rev. 2011 Feb 5. [Epub ahead of print]

  410. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy
    Krishnan SM, Dixit NM. PLoS Comput Biol. 2011 Feb 3;7(2)

  411. Pegylated-interferon-?(2a) in clinical practice: how to manage patients suffering from side effects
    Calvaruso V, Mazza M, Almasio PL. Expert Opin Drug Saf. 2011 Feb 16. [Epub ahead of print]

  412. Dendritic cells in hepatitis C infection: can they (help) win the battle?
    Dolganiuc A, Szabo G. J Gastroenterol. 2011 Feb 17. [Epub ahead of print]

  413. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
    Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Proc Natl Acad Sci U S A. 2011 Feb 14. [Epub ahead of print]

  414. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis
    Petta S, Tripodo C, Grimaudo S, Cabibi D, Cammà C, Di Cristina A, Di Marco V, Di Vita G, Ingrao S, Mazzola A, Marchesini G, Pipitone R, Craxì A. Dig Liver Dis. 2011 Feb 14. [Epub ahead of print]

  415. Psychiatrists' knowledge and practices in screening and assessment of Hepatitis C for inpatients with severe mental illness
    Lagios K, Deane F. Australas Psychiatry. 2011 Feb 25. [Epub ahead of print]

  416. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia
    Poordad F, Theodore D, Sullivan J, Grotzinger K. J Med Econ. 2011 Feb 25. [Epub ahead of print]

  417. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics
    Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]

  418. Novel Findings for the Development of Drug Therapy for Various Liver Diseases:Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C
    Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. J Pharmacol Sci. 2011 Feb 22. [Epub ahead of print]

  419. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Lobritto SJ, Schwarz KB, Robuck PR, Barton B, González-Peralta RP. Hepatology. 2011 Feb 23. [Epub ahead of print]

  420. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
    López V, Molina I, Monteagudo C, Jordá E. Int J Dermatol. 2011 Mar;50(3):287-91.

  421. Assessment of fibrosis and cirrhosis in liver biopsies: an update
    Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Semin Liver Dis. 2011 Feb;31(1):82-90. Epub 2011 Feb 22.

  422. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
    Ferenci P. Expert Opin Drug Saf. 2011 Feb 23. [Epub ahead of print]

  423. Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
    Gaglio PJ, Moss N, McGaw C, Reinus J. Dig Dis Sci. 2011 Feb 19. [Epub ahead of print]

  424. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-? plus ribavirin therapy in Taiwanese chronic HCV infection
    Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. Genes Immun. 2011 Feb 24. [Epub ahead of print]

  425. Prevention of virus hepatitis A to E.
    Cornberg M, Manns MP. Internist (Berl). 2011 Feb 23. [Epub ahead of print]

  426. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]

  427. 'Easy to Treat' genotypes were not created equal. Can rapid virological response (RVR) level the playing field?
    Duarte-Rojo A, Heathcote EJ, Feld JJ. J Hepatol. 2011 Feb 17. [Epub ahead of print]

  428. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
    Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group. J Hepatol. 2011 Feb 24. [Epub ahead of print]

  429. Mechanism of action of Ribavirin in a novel hepatitis C virus replication cell system
    Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Virus Res. 2011 Feb 11. [Epub ahead of print]

  430. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
    Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group. J Med Virol. 2011 Feb 25. doi: 10 [Epub ahead of print]

  431. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.

  432. U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for
    Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, Decomarmond C, Smith CI, McKee DP, Boyd W, Kulig CC, Bini EJ, Pedrosa MC. Dig Dis Sci. 2011 Jan 11. [Epub ahead of print]

  433. HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies
    Operskalski EA, Kovacs A. Curr HIV/AIDS Rep. 2011 Jan 11. [Epub ahead of print]

  434. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]

  435. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ, Lee SD. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:96-101.

  436. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1
    Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N. Eur J Clin Microbiol Infect Dis. 2011 Jan 13. [Epub ahead of print]

  437. IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
    Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. J Gen Virol. 2011 Jan 12. [Epub ahead of print]

  438. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]

  439. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ, Lee SD. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:96-101.

  440. Hepatitis C virus: How genetic variability affects pathobiology of disease
    Chayama K, Hayes CN. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:83-95.

  441. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1
    Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N. Eur J Clin Microbiol Infect Dis. 2011 Jan 13. [Epub ahead of print]

  442. IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
    Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. J Gen Virol. 2011 Jan 12. [Epub ahead of print]

  443. New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Asselah T, Marcellin P. Liver Int. 2011 Jan;31 Suppl 1:68-77.

  444. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C
    Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. J Hepatol. 2011 Jan 12. [Epub ahead of print]

  445. How to use virological tools for the optimal management of chronic hepatitis C
    de Leuw P, Sarrazin C, Zeuzem S. Liver Int. 2011 Jan;31 Suppl 1:3-12.

  446. Impact of a sustained virological response on the long-term outcome of hepatitis C
    Alberti A. Liver Int. 2011 Jan;31 Suppl 1:18-22.

  447. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
    Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. J Gastroenterol. 2011 Jan 19. [Epub ahead of print]

  448. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients
    Petta S, Craxì A. Liver Int. 2011 Jan;31 Suppl 1:36-44.

  449. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care
    McHutchison JG. Liver Int. 2011 Jan;31 Suppl 1:29-35.

  450. Future hepatitis C virus treatment: interferon-sparing combinations
    Gane E. Liver Int. 2011 Jan;31 Suppl 1:62-7.

  451. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?
    Castera L, Bedossa P. Liver Int. 2011 Jan;31 Suppl 1:13-7.

  452. Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic Hepatitis C patients
    de Almeida CM, de Lima TA, Castro DB, Torres KL, da Silva Braga W, Peruhype-Magalhães V, Teixeira-Carvalho A, Martins-Filho OA, Malheiro A. Scand J Immunol. 2011 Jan 13. [Epub ahead of print]

  453. Sustained virologic response among Latino veterans; does it represent the cure of chronic hepatitis C infection?
    De Jesús J, Nieves-Santiago P, Rodríguez-Pérez F, Toro DH. P R Health Sci J. 2010 Dec;29(4):397-401.

  454. Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis
    Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY; On Behalf Of The Swiss Hepatitis C Cohort Study Group. J Hepatol. 2011 Jan 11. [Epub ahead of print]

  455. Treatment of hepatitis C virus infection in patients with end-stage renal disease
    Liu CH, Kao JH. J Gastroenterol Hepatol. 2011 Feb;26(2):228-39.

  456. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
    Jamma S, Hussain G, Lau DT. Curr Hepat Rep. 2010;9(4):260-269.

  457. Hepatitis C virus Resistance to Protease Inhibitors
    Halfon P, Locarnini S. J Hepatol. 2011 Jan 29. [Epub ahead of print]

  458. Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study
    Gamage DG, Read TR, Bradshaw CS, Hocking JS, Howley K, Chen MY, Fairley CK. BMC Infect Dis. 2011 Feb 3;11(1):39. [Epub ahead of print]

  459. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads
    Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Hepatol Res. 2011 Feb;41(2):126-32.

  460. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin
    Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. World J Gastroenterol. 2011 Jan 28;17(4):493-8.

  461. Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C
    Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 Feb 2. [Epub ahead of print]

  462. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C
    Pattullo V, Heathcote EJ, Wong DK. Hepatol Int. 2010 Aug 8;4(4):723-31.

  463. Hepatitis C virus in primary care: survey of nurses' attitudes to caring
    Frazer K, Glacken M, Coughlan B, Staines A, Daly L. J Adv Nurs. 2011 Mar;67(3):598-608.

  464. Interferon lambdas: the next cytokine storm
    Kelly C, Klenerman P, Barnes E. Gut. 2011 Feb 8. [Epub ahead of print]

  465. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease
    Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 Feb 8. [Epub ahead of print]

  466. Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men
    Fierer DS. Curr Infect Dis Rep. 2010 Mar;12(2):118-25.

  467. Recommendations for the management of mixed Cryoglobulinemia syndrome in Hepatitis C virus-infected patients
    Pietrogrande M, Devita S, Zignego A, et al. Autoimmun Rev. 2011 Feb 5. [Epub ahead of print]

  468. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy
    Krishnan SM, Dixit NM. PLoS Comput Biol. 2011 Feb 3;7(2)

  469. Pegylated-interferon-?(2a) in clinical practice: how to manage patients suffering from side effects
    Calvaruso V, Mazza M, Almasio PL. Expert Opin Drug Saf. 2011 Feb 16. [Epub ahead of print]

  470. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis
    Petta S, Tripodo C, Grimaudo S, Cabibi D, Cammà C, Di Cristina A, Di Marco V, Di Vita G, Ingrao S, Mazzola A, Marchesini G, Pipitone R, Craxì A. Dig Liver Dis. 2011 Feb 14. [Epub ahead of print]

  471. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.

  472. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
    Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Proc Natl Acad Sci U S A. 2011 Feb 14. [Epub ahead of print]

  473. Dendritic cells in hepatitis C infection: can they (help) win the battle?
    Dolganiuc A, Szabo G. J Gastroenterol. 2011 Feb 17. [Epub ahead of print]

  474. Psychiatrists' knowledge and practices in screening and assessment of Hepatitis C for inpatients with severe mental illness
    Lagios K, Deane F. Australas Psychiatry. 2011 Feb 25. [Epub ahead of print]

  475. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics
    Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]

  476. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia
    Poordad F, Theodore D, Sullivan J, Grotzinger K. J Med Econ. 2011 Feb 25. [Epub ahead of print]

  477. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
    López V, Molina I, Monteagudo C, Jordá E. Int J Dermatol. 2011 Mar;50(3):287-91.

  478. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Lobritto SJ, Schwarz KB, Robuck PR, Barton B, González-Peralta RP. Hepatology. 2011 Feb 23. [Epub ahead of print]

  479. Novel Findings for the Development of Drug Therapy for Various Liver Diseases:Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C
    Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. J Pharmacol Sci. 2011 Feb 22. [Epub ahead of print]

  480. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-? plus ribavirin therapy in Taiwanese chronic HCV infection
    Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. Genes Immun. 2011 Feb 24. [Epub ahead of print]

  481. Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
    Gaglio PJ, Moss N, McGaw C, Reinus J. Dig Dis Sci. 2011 Feb 19. [Epub ahead of print]

  482. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
    Ferenci P. Expert Opin Drug Saf. 2011 Feb 23. [Epub ahead of print]

  483. Assessment of fibrosis and cirrhosis in liver biopsies: an update
    Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Semin Liver Dis. 2011 Feb;31(1):82-90. Epub 2011 Feb 22.

  484. Prevention of virus hepatitis A to E.
    Cornberg M, Manns MP. Internist (Berl). 2011 Feb 23. [Epub ahead of print]

  485. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]

  486. Mechanism of action of Ribavirin in a novel hepatitis C virus replication cell system
    Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N. Virus Res. 2011 Feb 11. [Epub ahead of print]

  487. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
    Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group. J Hepatol. 2011 Feb 24. [Epub ahead of print]

  488. 'Easy to Treat' genotypes were not created equal. Can rapid virological response (RVR) level the playing field?
    Duarte-Rojo A, Heathcote EJ, Feld JJ. J Hepatol. 2011 Feb 17. [Epub ahead of print]

  489. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
    Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group. J Med Virol. 2011 Feb 25. doi: 10 [Epub ahead of print]

  490. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    Williams IT, Bell BP, Kuhnert W, Alter MJ. Arch Intern Med. 2011 Feb 14;171(3):242-8.

  491. Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus
    Pawlotsky JM. Hepatology. 2011 Mar 3. doi: 10.1002/hep.24262. [Epub ahead of print]

  492. Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 Mar 3.. [Epub ahead of print]

  493. Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
    Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Dig Dis Sci. 2011 Mar 5. [Epub ahead of print]

  494. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
    Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154.

  495. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
    Tran HA, Jones TL, Ianna EA, Reeves GE. Thyroid Res. 2011 Jan 8;4(1):2. [Epub ahead of print]

  496. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses
    Houghton M. Immunol Rev. 2011 Jan;239(1):99-108.

  497. Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy
    Gonzalez SA, Keeffe EB. Front Biosci. 2011 Jan 1;16:225-50.

  498. Hepatitis C virus replication and potential targets for direct-acting agents
    O'Leary JG, Davis GL. Therap Adv Gastroenterol. 2010 Jan;3(1):43-53

  499. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients
    Burney T, Dusheiko G. Expert Rev Anti Infect Ther. 2010 Dec 14

  500. Evaluation of a New; Rapid Test for Detecting HCV Infection; Suitable for Use with Blood or Oral Fluid
    Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M. J Virol Methods. 2010 Dec 20

  501. Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection
    White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, Anand M, El-Serag HB. Dig Dis Sci. 2010 Dec 28.

  502. Thrombocytopenia in chronic hepatitis C
    Olariu M, Olariu C, Olteanu D. J Gastrointestin Liver Dis. 2010 Dec;19(4):381-5.

  503. Current therapies for chronic hepatitis C
    Ferguson MC. Pharmacotherapy. 2011 Jan;31(1):92-111.

  504. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-?-2a and ribavirin in HIV/HCV co-infected patients
    Vachon Marie-Louise C; Factor Stephanie H; Branch Andrea D; Fiel Maria-Isabel; Rodriguez-Torres Maribel; Bräu Norbert; Sterling Richard K; Slim Jihad; Talal Andrew H; Dieterich Douglas T; Sulkowski Mark S. Journal of hepatology 2011;54(1):41-7. 2. 2010.

  505. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C
    Asselah T. J Hepatol. 2010 Dec 15.

  506. Lymphocytosis as a predictor of poor response to treatment of hepatitis C
    Martinez-Camacho A, Khaoustov VI, Adam E, Lewis DE, Tavakoli-Tabasi S, Yoffe B. Gastroenterol Clin Biol. 2010 Dec 22.

  507. Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy
    Bortoletto G, Campagnolo D, Mirandola S, Comastri G, Severini L, Pulvirenti FR, Alberti A. J Clin Virol. 2010 Dec 29. [Epub ahead of print]

  508. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes
    Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T. Aliment Pharmacol Ther. 2010 Dec 29. [Epub ahead of print]

  509. Impact of hepatitis C in mortality in patients on hemodialysis
    Rabanal CP, Zevallos JC, Cusato RC. J Bras Nefrol. 2010 Dec;32(4):337-341.

  510. Hepatitis C virus: Up to the minute
    Roche B, Samuel D. Liver Transpl. 2010 Oct;16(S2):S26-S35.

  511. Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom
    Hakre S, Peel SA, O'Connell RJ, Sanders-Buell EE, Jagodzinski LL, Eggleston JC, Myles O, Waterman PE, McBride RH, Eader SA, Davis KW, Rentas FJ, Sateren WB, Naito NA, Tobler SK, Tovanabutra S, Petruccelli BP, McCutchan FE, Michael NL, Cersovsky SB, Scott PT. Transfusion. 2010 Oct 7. [Epub ahead of print]

  512. Seizures During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C: Observations From the WIN-R Trial
    Ahmed F, Jacobson IM, Herrera JL, Brand M, Wasserman RB, Fixelle AM, Rustgi VK, Albert C, Brown R, Brass C; for the WIN-R Study Group. J Clin Gastroenterol. 2010 Oct 6. [Epub ahead of print]

  513. Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis
    Russo MW. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):535-9.

  514. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C
    Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. Hepatology. 2010 Aug 20. [Epub ahead of print]

  515. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C
    Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A. Pharmacol Res. 2010 Oct 9. [Epub ahead of print]

  516. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
    de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Knegt RJ. Hepatology. 2010 Aug 19. [Epub ahead of print]

  517. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
    Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Aliment Pharmacol Ther. 2010 Oct;32(8):969-83. . Epub 2010 Aug 15.

  518. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
    Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Hepatology. 2010 Jul 29. [Epub ahead of print]

  519. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
    Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. BMC Gastroenterol. 2010 Sep 9;10(1):103. [Epub ahead of print]

  520. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy
    Tuma P, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V. Antivir Ther. 2010;15(6):881-6.

  521. Use of Statins in Patients with Chronic Hepatitis C
    Andrus MR, East J. South Med J. 2010 Sep 2. [Epub ahead of print]

  522. Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis
    Gonzalez-Candelas F, Guiral S, Carbo R, Valero A, Vanaclocha H, Gonzalez F, Bracho MA. Virol J. 2010 Sep 8;7(1):217. [Epub ahead of print

  523. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France
    Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F; the HCV surveillance steering committee, the HCV surveillance group and Jean-Claude Desenclos. J Med Virol. 2010 Oct;82(10):1647-1654.

  524. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy
    François C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, Castelain S, Duverlie G. J Med Virol. 2010 Oct;82(10):1640-6.

  525. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis
    Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. J Gastroenterol. 2010 Sep 10. [Epub ahead of print]

  526. The impact of smoking on incident type 2 diabetes in a cohort with hepatitis B but not hepatitis C infection
    Wang CS, Chang TT, Yao WJ, Wang ST, Chou P. Viral Hepat. 2010 Aug 31. [Epub ahead of print]

  527. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial
    Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Psychosomatics. 2010 Sep;51(5):401-8.

  528. von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4
    Pramhas S, Homoncik M, Ferenci P, Ferlitsch A, Scherzer T, Gangl A, Peck-Radosavljevic M. Antivir Ther. 2010;15(6):831-9.

  529. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C
    Rao GA, Pandya PK. Gastroenterology. 2010 Sep 9. [Epub ahead of print]

  530. Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities
    Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, Page K. Vaccine. 2010 Sep 7. [Epub ahead of print]

  531. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
    Guedj J, Neumann AU. J Theor Biol. 2010 Sep 10. [Epub ahead of print]

  532. Intensified peginterferon alfa-2a/ribavirin therapy for patients with HCV genotype 1, weight >/=85 kg and high viral load: randomized trial
    Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA; PROGRESS Study Investigators. Gastroenterology. 2010 Sep 2. [Epub ahead of print]

  533. A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon ? and Ribavirin
    Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A, Ignaccolo L, Vadalà G, Misseri M, Maiorca D, Mastrosimone G, Judica A, Palermo F. J Clin Gastroenterol. 2010 Sep 8. [Epub ahead of print]

  534. Hepatitis C virus infection: A "liaison a trois" amongst the virus, the host, and chronic low-level inflammation for human survival
    Barnaba V. J Hepatol. 2010 Jun 25. [Epub ahead of print]

  535. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; the HALT-C Trial Group. Gut. 2010 Jul 30. [Epub ahead of print]

  536. Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients
    Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M. J Infect Dis. 2010 Aug 2. [Epub ahead of print]

  537. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression
    Maluf DG, Archer KJ, Villamil F, Stravitz RT, Mas V. Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):445-58.

  538. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis
    Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Int J Infect Dis. 2010 Jul 31. [Epub ahead of print]

  539. Comparison of Immune Restoration in Early versus Late Interferon Alpha Therapy against Hepatitis C Virus
    Abdel-Hakeem MS, Bédard N, Badr G, Ostrowski M, Sékaly RP, Bruneau J, Willems B, Heathcote EJ, Shoukry NH. J Virol. 2010 Jul 28. [Epub ahead of print]

  540. Acute Hepatitis C: Diagnosis and Management
    McLean OR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2007;31:66-77.

  541. Management of Hepatitis C Virus Infection
    Tran LC, Woods AR, Herrera JL. Drug Benefit Trends 2004;16:266-276.

  542. Hepatitis C: Who should be treated?
    Smith JR, Herrera JL. PRACTICAL GASTROENTEROLOGY • SEPTEMBER 2002;26:14-21.

  543. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2003 Nov;98(11):2354-62.

  544. Increased prevalence of depression in hepatitis C infection patients
    Hjerrild S, Renvillard SG, Leutscher PD, Videbech P. Ugeskr Laeger. 2010 Jun 21;172(25):1889-1893.

  545. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros
    Masuzaki R, Yoshida H, Omata M. Dig Liver Dis. 2010 Jul;42 Suppl 3:S281-6.

  546. New Frontiers of HCV Therapy in HIV/HCV Co-infection
    Amorosa VK. Curr HIV/AIDS Rep. 2010 Jun 20. [Epub ahead of print]

  547. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy
    Hofer H, Aydin I, Neumueller-Guber S, Mueller C, Scherzer TM, Staufer K, Steindl-Munda P, Wrba F, Ferenci P. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]

  548. Gender influence on treatment of chronic hepatitis C genotype 1
    Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE. Rev Soc Bras Med Trop. 2010 Jun;43(3):217-23.

  549. Treatment options for HCV nonresponders and relapse patients
    Pearlman BL, Sjogren MH. Gastroenterol Hepatol (N Y). 2010 Mar;6(3 Suppl 6):1-12.

  550. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
    Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Carlos Lopez-Talavera J, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Hepatology. 2010 May 14. [Epub ahead of print]

  551. Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience
    Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, Heilman RL, Jorge. Transplantation. 2010 Jun 22. [Epub ahead of print]

  552. Evidence for separation of HCV subtype 1a into two distinct clades
    Pickett BE, Striker R, Lefkowitz EJ. J Viral Hepat. 2010 Jun 21. [Epub ahead of print]

  553. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. Hepatology. 2010 Jun 1. [Epub ahead of print]

  554. Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; and the HALT?C Trial Group. Hepatology. 2010 May 14. [Epub ahead of print]

  555. Treatment of hepatitis C in 2011: what can we expect?
    Shiffman ML. Curr Gastroenterol Rep. 2010 Feb;12(1):70-5.

  556. Boceprevir, an NS3 protease inhibitor of HCV
    Berman K, Kwo PY. Clin Liver Dis. 2009 Aug;13(3):429-39.

  557. The healthcare burden imposed by liver disease in aging Baby Boomers
    Davis GL, Roberts WL. Curr Gastroenterol Rep. 2010 Feb;12(1):1-6.

  558. Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality from Liver Cancer in the United States
    Younossi ZM, Stepanova M. Clin Gastroenterol Hepatol. 2010 Apr 29. [Epub ahead of print]

  559. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C
    Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S; Hokuriku Liver Study Group. Gastroenterology. 2010 Apr 28. [Epub ahead of print]

  560. IL28B Polymorphism Improves Viral Kinetics and Is the Strongest Pre-treatment Predictor of SVR in HCV-1 Patients
    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Gastroenterology. 2010 Apr 15. [Epub ahead of print]

  561. Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Gut Liver. 2009 Jun;3(2):108-15. Epub 2009 Jun 30.

  562. Preclinical Characterization of Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of HCV NS3 Protease
    Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge F. Antimicrob Agents Chemother. 2010 Mar 22. [Epub ahead of print]

  563. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS
    Farnik H, El-Duweik J, Welsch C, Sarrazin C, Lötsch J, Zeuzem S, Geisslinger G, Schmidt H. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4001-6.

  564. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data
    Wise M, Finelli L, Sorvillo F. Public Health Rep. 2010 May-Jun;125(3):414-22.

  565. Review article: HCV - STAT-C era of therapy
    Lange CM, Sarrazin C, Zeuzem S. Aliment Pharmacol Ther. 2010 Mar 31. [Epub ahead of print]

  566. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection
    Cross TJ, Quaglia A, Nolan J, Hughes S, Harrison PM. J Med Virol. 2010 May;82(6):958-64

  567. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus
    Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. Expert Opin Investig Drugs. 2010 Jan;19(1):151-9.

  568. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Med Virol. 2010 Apr;82(4):575-82.

  569. Telaprevir for previously treated chronic HCV infection
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. N Engl J Med. 2010 Apr 8;362(14):1292-303.

  570. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435
    Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. Antimicrob Agents Chemother. 2010 May;54(5):1878-87. Epub 2010 Feb 22.

  571. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy
    Anastasiou J, Alisa A,Virtue,S, Portmann,B, Murray-Lyon I, Williams R. Eur J Gastroenterol & Hepatol 2010;22:474-480

  572. Hepatitis C and metabolic syndrome
    Aparcero López R, Campo JA, Romero-Gómez M. Gastroenterol Hepatol. 2010 Mar 3. [Epub ahead of print]

  573. Genetic polymorphism and response to treatment in chronic hepatitis C: The future of personalized medicine
    Asselah T. J Hepatol. 2010 Jan 7. [Epub ahead of print]

  574. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels
    Barril G, Bartolomé J, Sanz P, Buoncristiani E, Traver JA, Selgas R, Buoncristiani U, Castillo I, Quiroga JA, Carreño V. J Med Virol. 2010 Mar 24;82(5):763-767. [Epub ahead of print]

  575. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions
    Bini EJ, Perumalswami PV. Hepatology. 2009 Nov 30. [Epub ahead of print]

  576. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study
    Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Drug Alcohol Depend. 2010 Mar 22. [Epub ahead of print]

  577. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma
    Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Mayo Clin Proc. 2010 Apr;85(4):349-56.

  578. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy
    Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M. Pediatr Blood Cancer. 2010 Feb 1. [Epub ahead of print]

  579. Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients
    Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE; for the Virahep-C Study Group. PLoS One. 2010 Feb 3;5(2):e9032

  580. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials
    Fabrizi F, Dixit V, Messa P, Martin P. J Med Virol. 2010 Mar 24;82(5):768-775. [Epub ahead of print]

  581. Multiple Clusters of Hepatitis Virus Infections Associated with Anesthesia for Outpatient Endoscopy Procedures
    Gutelius B, Perz JF, Parker MM, Hallack R, Stricof R, Clement EJ, Lin Y, Xia GL, Punsalang A, Eramo A, Layton M, Balter S. Gastroenterology. 2010 Mar 27. [Epub ahead of print]

  582. Molecular epidemiology of health care-associated transmission of hepatitis B and C viruses
    Holmberg SD. Clin Liver Dis. 2010 Feb;14(1):37-48

  583. Hepatitis B and Hepatitis C Prevalence and Treatment Referral Among Asian Americans Undergoing Community-Based Hepatitis Screening
    Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Am J Public Health. 2010 Feb 10. [Epub ahead of print]

  584. Treatment of hepatitis C in children
    Jara P, Hierro L. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):51-61.

  585. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin
    Levast M, Larrat S, Thelu MA, Nicod S, Plages A, Cheveau A, Zarski JP, Seigneurin JM, Morand P, Leroy V. J Med Virol. 2010 Mar 24;82(5):747-754. [Epub ahead of print]

  586. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C
    Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Kidney Int. 2010 Mar 31. [Epub ahead of print]

  587. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies
    Maccannell T, Laramie AK, Gomaa A, Perz JF. Clin Liver Dis. 2010 Feb;14(1):23-36.

  588. Management of Acute Hepatitis C
    Maheshwari A, Thuluvath PJ. Clin Liver Dis. 2010 Feb;14(1):169-176.

  589. Performance of the AST-to-Platelet Ratio Index as a Noninvasive Marker of Fibrosis in Pediatric Patients With Chronic Viral Hepatitis
    McGoogan KE, Smith PB, Choi SS, Berman W, Jhaveri R

  590. Infection Control Guidelines for Prevention of Health Care-Associated Transmission of Hepatitis B and C Viruses
    Michelin A, Henderson DK. Clin Liver Dis. 2010 Feb;14(1):119-136.

  591. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features
    Morsica G, Ancarani F, Bagaglio S, Maracci M, Cicconi P, Cozzi Lepri A, Antonucci G, Bruno R, Santantonio T, Tacconi L, Baldelli F, Piscopo R, Santoro D, Lazzarin A, D'Arminio Monforte A; HepaICONA; ICONA Study Groups. Infection. 2009 Oct;37(5):455-60.

  592. Hepatitis C and hepatic steatosis
    Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. QJM. 2010 Feb 4. [Epub ahead of print]

  593. US Outbreak Investigations Highlight the Need for Safe Injection Practices and Basic Infection Control
    Perz JF, Thompson ND, Schaefer MK, Patel PR. Clin Liver Dis. 2010 Feb;14(1):137-51

  594. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
    Seden K, Back D, Khoo S. J Antimicrob Chemother. 2010 Mar 23. [Epub ahead of print]

  595. Epidemiology of Hepatitis B and C Viruses: A Global Overview
    Te HS, Jensen DM. Clin Liver Dis. 2010 Feb;14(1):1-21.

  596. Terlipressin therapy for renal failure in cirrhosis
    Triantos C, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli,L, Leandro,G, Patch D, Burroughs A. Eur J Gastroenterol & Hepatol 2010;22:481-486.

  597. The Treatment of Chronic Hepatitis C Virus Infection in HIV Co-infection
    Vogel M, Rockstroh J. Eur J Med Res. 2009 Dec 14;14(12):507-15.

  598. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients
    Winters MA, Chary A, Eison R, Asmuth D, Holodniy M. J Med Virol. 2010 Mar 24;82(5):791-798. [Epub ahead of print]

  599. Genetic polymorphism and response to treatment in chronic hepatitis C: The future of personalized medicine
    Asselah T. J Hepatol. 2010 Jan 7. [Epub ahead of print]

  600. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions
    Bini EJ, Perumalswami PV. Hepatology. 2009 Nov 30. [Epub ahead of print]

  601. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy
    Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M. Pediatr Blood Cancer. 2010 Feb 1. [Epub ahead of print]

  602. Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients
    Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE; for the Virahep-C Study Group. PLoS One. 2010 Feb 3;5(2):e9032.

  603. Molecular epidemiology of health care-associated transmission of hepatitis B and C viruses
    Holmberg SD. Clin Liver Dis. 2010 Feb;14(1):37-48.

  604. Hepatitis B and Hepatitis C Prevalence and Treatment Referral Among Asian Americans Undergoing Community-Based Hepatitis Screening
    Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Am J Public Health. 2010 Feb 10. [Epub ahead of print]

  605. Treatment of hepatitis C in children
    Jara P, Hierro L. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):51-61.

  606. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies
    Maccannell T, Laramie AK, Gomaa A, Perz JF. Clin Liver Dis. 2010 Feb;14(1):23-36.

  607. Management of Acute Hepatitis C
    Maheshwari A, Thuluvath PJ. Clin Liver Dis. 2010 Feb;14(1):169-176

  608. Performance of the AST-to-Platelet Ratio Index as a Noninvasive Marker of Fibrosis in Pediatric Patients With Chronic Viral Hepatitis
    McGoogan KE, Smith PB, Choi SS, Berman W, Jhaveri R

  609. Infection Control Guidelines for Prevention of Health Care-Associated Transmission of Hepatitis B and C Virusese
    Michelin A, Henderson DK. Clin Liver Dis. 2010 Feb;14(1):119-136

  610. Hepatitis C and hepatic steatosis
    Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. QJM. 2010 Feb 4. [Epub ahead of print]

  611. US Outbreak Investigations Highlight the Need for Safe Injection Practices and Basic Infection Control
    Perz JF, Thompson ND, Schaefer MK, Patel PR. Clin Liver Dis. 2010 Feb;14(1):137-51.

  612. Epidemiology of Hepatitis B and C Viruses: A Global Overview
    Te HS, Jensen DM. Clin Liver Dis. 2010 Feb;14(1):1-21.

  613. The Treatment of Chronic Hepatitis C Virus Infection in HIV Co-infection
    Vogel M, Rockstroh J. Eur J Med Res. 2009 Dec 14;14(12):507-15

  614. Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C
    Gambarin-Gelwan M, Jacobson IM. J Viral Hepat 2008;9:623-33.

  615. Host Genetics, Steatosis and Insulin Resistance among African Americans and Caucasian Americans with Hepatitis C Virus Genotype-1 Infection
    Iuliano AD, Feingold E, Wahed AS, Kleiner DE, Belle SH, Conjeevaram HS, Zmuda J, Liang TJ, Yee LJ. Intervirology 2009;52:49-56.

  616. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
    John G. McHutchison, M.D., Gregory T. Everson, M.D., Stuart C. Gordon, M.D., Ira M. Jacobson, M.D., Mark Sulkowski, M.D., Robert Kauffman, M.D., Lindsay McNair, M.D., John Alam, M.D., Andrew J. Muir, M.D., for the PROVE1 Study Team. N ENGL J Med 2009;360:1827-1838

  617. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
    Christophe Hézode, M.D., Nicole Forestier, M.D., Geoffrey Dusheiko, M.D., Peter Ferenci, M.D., Stanislas Pol, M.D., Tobias Goeser, M.D., Jean-Pierre Bronowicki, M.D., Marc Bourlière, M.D., Shahin Gharakhanian, M.D., Leif Bengtsson, B.S.C., Lindsay McNair, M.D., M.P.H., Shelley George, M.D., Tara Kieffer, Ph.D., Ann Kwong, Ph.D., Robert S. Kauffman, M.D., Ph.D., John Alam, M.D., Jean-Michel Pawlotsky, M.D., Ph.D., Stefan Zeuzem, M.D., for the PROVE2 Study Team. N ENGL J Med 2009;360:1839-1850.

  618. Adherence to medication for chronic hepatitis C: Building on the model of human immunodeficiency virus antiretroviral adherence research
    Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D.Ailiment Pharmacol Ther. 2009 Mar 26 (Epub ahead of print)

  619. Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection
    Puchner KP, Berg T. Z Gastroenterol. 2009;47:446-456. Epub 2009 May 5.

  620. Neuropsychological performance in patients with human immunodeficiency (HIV) and neuropsychological hepatitis C virus (HCV) coinfection
    Failde J, Rodríguez Alvarez M, López Castro J, Simón López M. Neurologia. 2009;3:154-9.

  621. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men
    van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM, Danta M. Gastroenterol. 2009;136:1609-17.

  622. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection
    Gonzalez SA, Fiel MI, Sauk J, Canchis PW, Liu RC, Chiriboga L, Yee HT, Jacobson IM, Talal AH. J Viral Hepat. 2009;2:141-8.

  623. Peginterferon alfa-2b and Ribavirin: Effective in Patients with Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
    Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; The Epic Study Group. Gasterenterol 2009;Jan 22 (Epub ahead of print)

  624. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors
    Kwong AD, McNair L, Jacobson I, George S.Curr Opin Pharmacol 2008;5:522-31.

  625. Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study
    Loras C, Saro C, Gonzalez-Huix F, et al. Am J Gastroenterol 2009;104:57-63.

  626. Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
    Di Bisceglie A, Shiffman M, Everson G, et al for the HALT-C Trial Investigators. N Engl J Med 2008;359:2429-2441.

  627. Exceeding the limits of liver histology markers
    Mehta S, Lau B, Afdhal N and Thomas D. J Hepatol 2009;50:36-41.

  628. A Randomized, Prospective Trial of Ribavirin 400 mg/Day Versus 800 mg/Day in Combination with Peginterferon Alfa-2a in Hepatitis C Virus Genotypes 2 and 3
    Ferenci P, Brunner H, Laferl H, Scherzer T, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K, for the Austrian Hepatitis Study Group. HEPATOLOGY;47:1816-1823.

  629. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3
    Poustchi H, Negro F, Hui J, Homer I, Cua Y, Brandt L, Kench J, George J. J Hepatol 2008;48:28-34.

  630. Combination of Oxidative Stress and Steatosis Is a Risk Factor for Fibrosis in Alcohol-Drinking Patients With Chronic Hepatitis C
    Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Am J Gastroenterol 2008;103:147-153.

  631. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C
    McHutchinson J, Dusheikko G, , Schiffman M, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon S, Campbell F, Theodore D, Blackman N, Jenkins J, Afdhal N for the TPL102357 Study Group. N ENGL J MED 357,22:2227-2236.

  632. Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1-Infected Slow Responders
    Pearlman B, Ehleben C, Saifee S. HEPATOLOGY 2007;6:1688-1694.

  633. Predictors of Response of U.S. Veterans to Treatment for the Hepatitis C Virus
    Backus LI, Boothroyd DB, Phillips BR, Mole LA. HEPATOLOGY 2007 ; 46:37-47.

  634. Telaprevir and Pegylated Interferon-alpha-2a Inhibit Wild-Type and Resistant Genotype 1 Hepatitis C Virus Replication in Patients
    Kieffer T, Sarrazin C, Miller J, Welker M, Forestier N, Reesink H, Kwong A, Zuezem S

  635. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
    Schiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola´ R, Shafran SD, Barange K, Lin A, Sorman A, Zeuzem S, for the ACCELERATE Investigators. NEJM 2007 ; 357:124-134

  636. Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication
    Huang J, Dai C, Hwang, Ho C, Hsiao P, Hsieh M, Lee L, Lin Z, Chen S, Hsieh M, Wang L, Shin S, Chang W, Chuang W, Yu M. Am J Gastroenterol 2007 ; 102:1237-1243

  637. Cognitive Function Does Not Worsen During Pegylated Interferon and Ribavirin Retreatment of Chronic Hepatitis C
    Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok AS, Kronfol Z, Padmanabhan L, and the HALT-C Trial Group. HEPATOLOGY 2007 ; 45:1154-1163

  638. The Effects of HCV Infection and Management on Health-Related Quality of Life
    Younossi Z, Kallman J, Kincaid J. HEPATOLOGY 2007;45:806-816

  639. HCV RNA Detection by TMA during the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    C. Morishima et al. HEPTOLOGY, Vol. 44, No. 2, 2006:360-367

  640. Impact of Disease Severity on Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons From the HALT-C Trial
    Everson G, Hoefs J, Seeff L, Bonkovsky H, Naishadham D, Schiffman M, Kahn J, Lok A, De Bisceglie, Lee W, Dienstag J, Ghany M, Morishima C, and the HALT-C Trial Group. HEPATOLOGY 2006 ; 44:1675-1684

  641. Cost-Effectiveness of Hematologic Growth Factors for Anemia Occurring During Hepatitis C Combination Therapy
    R Del Rio, Anthony B. Post, Mendel Singer. Hepatology 2006; 44:1598-1606

  642. Steatosis and Progression of Fibrosis in Untreated Patients With Chronic Hepatitis C Infection
    P. Perumalswami et al. HEP, Vol 43, No 4 (April 2006); 780-787

  643. Treatment with daily concensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study
    M. Cornberg et al. Journal of Hepatology 44 (Feb 2006) 291-301

  644. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    S. Zeuzem et al J Hep 44 (January 2006) 97-103

  645. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse
    M Gerotto et al, J Hep 44 (January 2006) 83-87

  646. HCV/Clinical: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin
    Ferenci P et al J Hep 43 (2005) 425-433.

  647. HCV/Clinical: Pilot study of interferon gamma for chronic hepatitis C
    A. Soza, T. Heller, M. Ghany, G. Lutchman, T. Liang, J. Germain, H. Hsu, Y. Park, J. Hoofnagle Journal of Hepatology 43 (2005) 67-71.

  648. HCV/Clinical: Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C
    WL Krawitt et al. J.Hep 43 (2005) 243-249

  649. HCV/Clinical: Adult living donor liver transplantation: Who is the ideal donor and recipient?
    Henkie P et al. J Hep. Volume 43 (2005) 13-17
   

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2011 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource
for US healthcare providers only. Use of this Web site is governed by the CLD Foundation terms of use and privacy statement.